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ABSTRACT 
Recent studies have shown that the proliferation of various human and 
murine tumour lines can be inhibited by the addition of 
gamma-linolenic acid (GLA) to the culture medium. These findings are 
consistent with the proposal put forward by Horrobin (1980) that 
malignant cells lack the enzyme/ A 6 desaturase; which is responsible 
for the conversion of linoleic acid (LA) to GLA. Since GLA is a 
prostaglandin (PG) precursor/ inadequate conversion of LA to GLA would 
result in decreased production of PGs/ particularly PGEi/ which has 
been shown to have an inhibitory effect on cell growth. Provision of 
GLA to enzyme deficient malignant cells should therefore bypass this 
blockade/ increase PGET synthesis and thus "normalise malignant 
cells". 
This study was performed to examine further the effects of exogenous 
GLA on growth of malignant cells in vitro and in vivo. Cells of the 
continuous murine sarcoma (M52B) line and primary cultures of non 
malignant fibroblasts were used to investigate effects of GLA in 
vitro. Cultures were exposed to either single or multiple doses of a 
range of concentrations of GLA. Radioimmunoassay (RIA) was performed 
to compare the amounts of PGE and PGF released into the medium by GLA 
treated and control M52B cultures and thus determine whether the 
addition of GLA in vitro significantly affected production of these 
PGs. 
v/i 
Athymic BALB/c mice and immunocompetent BALB/c and Biozze mice as well 
as mice of the "Onderstepoort Strain" were used in various in vivo 
studies. Tumours were induced by the subcutaneous inoculation of 
approximately 1 x 106 cells of either the M52B line (into 
immunocompetent and athymic mice) or human breast carcinoma (NUB 1) 
line (into athymic mice). Take rates and latent periods were 
recorded. GLA treatment was initiated after tumours were established. 
In one study the fatty acid in hydrogenated coconut oil (HCO), which 
contains no PG precursors/ was administered parenterally (100 
ug/ml/day) to Biozze mice. Control mice were either untreated or 
injected with HCO only. In another study, BALB/c mice and mice of the 
"Onderstepoort Strain" had their diet supplemented with GLA (in the 
form of EPO) to an extent of 3.5%. Control mice consumed either 
standard laboratory chow only or, chow supplemented with either 35% 
sunflower seed oil (SSO) or 35% HCO/ neither of which contain GLA. 
All diets were supplied ad libitum. Tumour sizes were measured every 
48 hours and at the end of each experiment at which time tumours were 
excised and examined histologically. 
GLA was found to produce inhibitory and toxic effects on growth of 
both M52B cells and non malignant fibroblasts in vitro/ although the 
effect in the latter was observed only with high concentrations of the 
fatty acid. The inhibition of malignant cell growth was concentration 
dependant and was positively related to the duration of exposure to 
the fatty acid. Prior to death/ cells treated with GLA accumulated 
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paranuclear granules which were shown histochemically to be lipid in 
nature. Electron microscopy confirmed the presence of large lipid 
deposits. Cultured M52B cells treated with GLA also released more PGE 
and PGF into the medium than did cells not exposed to the fatty acid. 
However, analysis of results using the Mann Whitney U test showed 
these differences to be statistically non significant for both PGE and 
PGF on two tailed tests. 
In contrast to the inhibition of M52B cell growth observed in vitro, 
growth of solid M52B sarcomas and NUB 1 carcinoma xenografts in 
athymic mice was apparently unaffected by administration of dietary 
GLA. Analysis of data using an unpaired student's t-test showed that 
the differences in tumour volumes between control and treated groups 
were not statistically significant either before or at the end of the 
experiment. 
While the inhibition of malignant cell growth caused by GLA in vitro 
was consistent with Horrobin's proposal that malignant cells may lack 
this PG precursor, whether or not these actions are mediated by the 
PGs remains obscure. Although an increase in PGE production by M52B 
cells was observed following GLA treatment, besides this increase 
being statistically non significant, it was not possible to determine 
whether this was due to PGE, (as suggested by Horrobin) or PGE2. 
It is possible that the effect produced in vitro was due to some 
factor other than raised PGE production, for example a non-specific 
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fat-overload effect or a change in cell membrane fluidity. The lack 
of effect of GLA on tumour growth in vivo may have been due to 
inadequate delivery of the fatty acid to the tumour site. However, 
whatever the mechanism of action of GLA in vitro/ since oral GLA was 
supplemented to the maximum tolerated extent and produced no effect in 
immunodeficient mice inyiyo, it would seem that in a similar clinical 
situation oral doses which would be practical may be ineffective. 
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Cancer, a disorderly, purposeless growth of cells, is currently 
one of the major causes of mortality (Endicott, 1972). The 
transformation of a normal cell to a cancer cell may be 
promoted by a variety of stimuli including viruses, radiation 
and chemicals (Honn et al., 1981). However, since the exact 
mechanism of transformation is unclear, much of cancer research 
is at present directed towards elucidating this mechanism and 
subsequently establishing a cure for the disease. Included 
amongst the many factors that are currently being investigated 
are the prostaglandins (PGs) which may play some role in 
regulation of cell division (Ames, 1983) and therefore be 
important in malignancy (Honn et al., 1981). 
PROSTAGLANDINS AND THEIR PRECURSORS 
The prostaglandins (PGs) are a group of naturally occurring 
unsaturated fatty acids which are widely distributed in both 
plant and animal kingdoms (Horrobin, 1978). They appear to be 
synthesised in virtually all mammalian tissues (Moncada and 
Vane, 1983), being produced "on demand" and then rapidly 
catabolised (Ziegler, 1982). PGs mediate a variety of 
biological effects and seem to play some role in almost all 
systems in the body (Karmali, 1980). 
Chemistry/ Biosynthesis and Metabolism 
The PGs which are structurally related to prostanoic acid 
(Granstrcwi/ 1977)(Figure 1) may be subdivided into three main 
naturally occurring groups; the 1/ 2 and 3 series having 1/ 2 
and 3 double bonds in their side chains respectively. PGs are 
named A/ B, C, D; E and F according to substituents on the 
pentane ring (Figure 1). More recently/ further related 
products of arachidonic acid (AA) metabolism, namely 
prostacyclin/ thromboxanes/ leukotrienes/ hydroperoxy and 
hydroxy fatty acids have been discovered (Honn et al., 
1981)(Figure 2). The PGs are derived from the essential fatty 
acids (EFAs) linoleic acid (LA) and alpha-linolenic acid (ALA)/ 
the former being the most important polyunsaturated fatty acid 
(PUFA) in the normal mammalian diet (Horrobin/ 1978). Cis LA 
(cLA) is found in large quantities in many vegetable oils 
including evening primrose oil (EPO - which contains 72% cLA)/ 
safflower (73% cLA)/ corn (57% cLA) and sunflower seed oil (SSO 
which contains 58% cLA) (Scholkens et al./ 1982)/ while smaller 
quantities are present in meat (Horrobin/ 1978). The synthesis 
of PGs of the 1 and 2 series from clA is shown in Figure 2. 
The immediate precursor of the 1 series is dihomogammalinolenic 
acid (DGLA; 8/11/14 - eicosatrienoic acid)/ and that of the 2 
series is arachidonic acid (AA; 5/18,11,14 - eicosatetraenoic 
acid). The 3 series PGs are formed from alpha linolenic acid 
(ALA; 5,8,11/14/17 - eicosapentaenoic acid). 
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Postulated role of PGs 
In addition to being ubiquitous/ PGs have been found to play 
some role in most tissues of the body (Nakano; 1972). They 
appear to act locally/ affecting only the activity of the 
tissue in which they are formed. Characterisation of their 
biological roles has been difficult because the effects of PGs 
vary according to the concentration and type of PG; and the 
site of action and species of animal (Ziegler/ 1982). At 
present/ there is no evidence to suggest that they are 
circulating hormones. However/ these substances are known to 
play a regulatory role in the reproductive/ renal/ neural/ 
immune and cardiovascular systems (Horrobin/ 1978; Karmali/ 
1980). Furthermore there is also evidence that PGs are 
involved in regulation of cell growth (Ziegler/ 1982). 
1 PGs and Cell Growth 
The possible role of PGs in the control of cell proliferation 
was based originally on the observation that these substances 
induced accumulation of intracellular cyclic AMP (cAMP) which 
inhibited uncontrolled proliferation of slime moulds 
(Droller/ 1981). More recent investigations using various 
malignant cell lines have since confirmed the finding that 
exogenous cAMP inhibits cell growth (Droller et al. / 1981; 
Dubpernell and Gavurin/ 1978; Honn et al./ 1981; Karmali/ 
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1980; Naseem and Hollander, 1973; Sheppard, 1972; Thomas 
et al., 1974). There is also considerable direct evidence to 
support a role for PGs in control of cell proliferation even 
though workers have produced different results with varying 
concentrations of these substances (Horrobin, 1978; Karmali, 
1980). This could be expected if cAMP is involved as it 
stimulates and inhibits cell proliferation at low and high 
concentrations respectively (Sheppard, 1972; Karmali, 1980). 
Exogenous PGET (Johnson and Pastan, 1971; Kurtz et al., 
1974; Pelus et al., 1979; Sheppard, 1972; Smith et al., 
1984), PGE2 (Delescluse et al., 1974; Pelus et al., 1979; 
Smith et al., 1984; Taylor and Polgar, 1977) and PGBĵ  (Smith 
et al., 1984; Johnson and Pastan, 1971) have been reported 
to suppress growth and to simultaneously elevate cellular 
cAMP production (Johnson and Pastan, 1971; Polgar and 
Taylor, 1977) in various cultured normal cells. 
In addition, the PG precursors LA, GLA, DGLA and AA generally 
have also been reported to affect growth of cultured non 
malignant cells, producing either inhibition or stimulation 
at low concentrations (Huttner et al., 1978; Wicha et al., 
1979) and inhibition of cell proliferation at higher 
concentrations (Begin et al., 1985; Booyens et al., 1984b; 
Huttner et al., 1978; Petry et al., 1984). The ability of 
these PUFAs to affect cell growth appears to be specific for 
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2.1 CELL LINES 
A primary culture is initiated from cells/ tissues or organs 
taken directly from an organism. This culture develops into a 
cell line which; when it has developed the potential to be 
subcultured indefinitely in vitro/ has been subcultured at 
least 70 times at intervals of 3 days and is capable of being 
frozen/ successfully thawed and regrown is designated a 
continuous cell line (Paul/ 1970). 
Two continuous malignant cell lines/ M52B derived from a murine 
sarcoma and NUB 1 derived from a human breast carcinoma/ were 
used in this study which investigated the effects of GLA on 
malignant cells growing both in vitro and in vivo. In 
addition/ primary cultures of non malignant fibroblasts were 
initiated from dorsal surface skin of adult BALB/c nude mice/ 
in order to examine the effects of GLA on normal cells. 
2.1.1 Murine Sarcoma M52B Line 
No literature pertaining to the M52B line could be found. M52B 
cells were obtained from Dr D.W. Verwoerd/ Veterinary Research 
Institute/ Onderstepoort/ who originally received the line from 
the National Cancer Institute/ Bethesda; Maryland. 
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The only information available indicated that the line: 
(i) was derived from a subcutaneous murine sarcoma 
(ii) produced the murine sarcoma (MUS) and murine 
leukaemia (MUL) viruses and 
(iii) transplanted efficiently in newborn BALB/c mice 
following subcutaneous inoculation of approximately 
106 cells. 
2 Human Breast Carcinoma Line (NUB 1) 
Cells of the NUB 1 line were obtained from Dr K.M.Robinson, 
University of Natal Medical School, Durban. The line was 
derived by passaging a poorly differentiated human breast 
carcinoma through nude mice. Well differentiated xenografts 
were removed and explants cultured. The resultant NUB 1 line 
consists of uniform tightly adherent epithelial cells lacking 
cytoplasmic oestrogen and progesterone receptors (R.Pegoraro, 
pers. comm.*). 
* Mrs.R.Pegoraro, Department of Chemical Pathology, 
University of Natal Medical School, Durban. 
Figure 3: A schematic representation of the dry explant technique 
tumour 





(2) Tumour excised aseptically 
and placed in sterile 
bottle containing MEM 
tumour explant 
MEM bathing explant 
tissue culture flask 
(9) incubated flask thereafter 
in the horizontal 
position such that MEM 
bathed the explants 
\ 
(8) incubated ^ 
flask in 
this position 
for 30 minutes 
to aid explant 
attachment 
(7) added 3 ml MEM to 
each flask in the 
vertical position such 
that MEM did not 
bathe the explants 
non tumour tissue 
tumour tissue 
petri dish 
(3) Placed tumour tissue 
in sterile petri dish and 
cleared non tumour tissue 
away from tumour V 
tumour 
explant 
(6) Placed about 10 
pieces of tumour 
tissue in each 
flask as shown 
above 
(4) Minced tumour into fine 











(5) placed minced pieces of tumour 
tissue into flask using pasteur 
pipette 
22 
Figure 4: Figure showing tissue culture flask containing 9 explants 
of murine sarcoma tissue 
E = explant 
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2.7 CELL STAINING 
2.7.1 May-Grunwald / Giemsa Method 
For observation of morphological features, cultured cells were 
stained by the May-Grunwald/Giemsa technique. The culture 
medium was decanted from the flask and 5 ml of 0.25% 
May-Grunwald (Gurr) in methanol added. After 6 minutes cells 
were rinsed twice with tap water and 5 ml of 5% Giemsa (Gurr) 
in water added for a further 6 minutes. Cells were again 
washed twice with tap water and air dried. 
2.7.2 Trypan Blue 
The dye exclusion test for cell viability (Philips/ 1973) was 
performed using a 0/25% aqueous solution of trypan blue. 
Approximately 0.1 ml of the dye was added to 5 ml culture 
medium and the cells viewed after 10 minutes, viable cells did 
not take up the stain. 
2.8 CELL OBSERVATION 
2.8.1 Macroscopic viewing 
A rapid method of assessing cell density was to view culture 
26 
flasks against a light source. Cu'tures that exhibited a 
"white-mat" appearance were trypsinized. Stained cells were 
also viewed macroscopically. 
2.8.2 Light Microscopy 
Unstained cells were routinely viewed with an Olympus CK II 
inverted phase contrast light microscope at a magnification of 
X100 using green and neutral density grey filters, viewing of 
stained cells did not necessitate the usage of a phase contrast 
microscope. 
2.8.3 Photography of Cells 
All photomicrographs of actively dividing cultured cells were 
taken on a Zeiss photomicroscope 3 with an interference filter 
and llford Pan F film (ASA 50) which was developed in 1:50 
Rodinal. 
2.8.4 Electron Microscopy 
In order to examine cell morphology and detect virus 
production, cultured M52B cells (control and GLA treated) ware 
prepared for electron microscopy according to the method of 
Robinson and Gregory (1978) as described below: 
Semi-confluent cultures were rinsed in MEM; fixed in 1% 
glutaraldehyde in MEM, postfixed in 1% osmium tetroxide and 
embedded in araldite. Ultrathin sections (60-80 nm) were cut 
vertically on the Nova Ultra tome with the araldite on the one 
side and the plastic of the flask on the other as described by 
Keen etal. (1973). These sections were then mounted on 
uncoated copper grids and stained with uranyl acetate and lead 
citrate (Reynolds/ 1963: Watson, 1958). 
Cultured M52B cells were viewed using a Zeiss EM 10B 
transmission electron microscope. All photographs were taken 
at 60 kv using Kodak electron image film 4489 which was 
developed in D19 (diluted 1+2 in water) and fixed in Amphix. 
FREEZING OF CULTURED CELLS AND TUMOURS 
Cultured Cells 
For storage purposes, semi-confluent cultures were frozen 
according to the method of Bertoleni et al. (1976) in MEM 
supplemented with 20% foetal calf serum and 10% dimethyl 
sulphoxide (freezing medium). A measured 5 ml of freezing 
medium was added to cultures. Flasks were sealed, covered in 
aluminium foil and labelled. The procedure of freezing to 
-70°C was controlled over a period of 150 minutes as follows: 
Flasks were incubated at 4°C for the first half hour, at - 4°C 
for the next 2 hours and finally at - 7o C in a Specht ultra 
deep freeze for the remaining storage period. Flasks were 
positioned horizontally during the freezing process. 
Thawing of cells was performed rapidly at 37°c. The freezing 
medium was decanted and 5 ml fresh MEM containing 10% foetal 
calf serum/ added. The pH of the culture medium was then 
adjusted and cells incubated at 37°C. 
2 Explanted Tumours 
Tumours were excised aseptically and placed in sterile/ labelled 






3.1 CHARACTERISATION OF THE M52B LINE 
The continuous murine cell line was characterised in the 
following ways: 
(i) by assessing tumorigenicity in vivo in BALB/c/ Biozze 
and Swiss Albino ("Onderstepoort strain") mice (Section 
4.3) 
(ii) by histopathological examination of tumours (Section 
4.6) 
(iii) by assessing growth and behaviour of M52B cells in vitro 
(Section 2) 
(iv) by examining the ultrastructure of M52B cells growing in 
vitro and in vivo (Section 2.8.4). 
3.2 INVESTIGATION OF SOME OF THE EFFECTS OF GLA 
In vitro studies were conducted on dense (approximately 
2 - 4 x 10 cells per flask) and less dense (approximately 
1.2 x 106 cells per flask) cultures of M52B cells as well as on 
primary cultures of non malignant fibroblasts (primary cultures 
As the nude mouse is immunologically incompetent/ it is highly 
susceptible to infection by foreign organisms. Therefore/ in 
addition to the standard practices of mouse husbandry described 
for conventional systems, a specific pathogen free environment 
(SPF-4) was created for these animals. 
MAINTENANCE OF MICE 
1 Immunocompetent Mice 
Immunocompetent mice were maintained under conventional 
temperature and humidity conditions. 
2 Nude Mice 
The nude mice were housed in a room designed with an entrance 
"trap" area as shown in Figure 5. The room was initially 
prepared by sealing off of all openings to the outside and 
thorough cleaning of all surfaces. A positive flow of filtered 
air through a thermo regulatory air conditioner (Homeaire) 
maintained a temperature of 25°C. 
The 9 m room was sterilized with paraformaldehyde vapour 
produced by adding 300 ml 40% w/v formaldehyde to 100 g 
potassium permanganate. 
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Figure 5; The Nude Mouse Room 
A - AIR CONDITIONER 
B - WORK BENCH 
C - CAGE RACK 
D - TRAP AREA 
E - SPF ENVIRONMENT 
F - SHELF 
G - OBSERVATION WINDOWS 
H - DOORS 
I - CUPBOARDS 
J - SEALED WINDOWS 
36 
Following this procedure sterility was promoted by a 
continuously burning 30 watt ultraviolet germicidal lamp. 
Autoclaved supplies of food, water, sawdust, gowns, caps and 
shoes were stored in the "trap" area for a minimum of 24 hours 
before use. 
The trap area was also used by personnel to dress in sterile 
cap, mask, gown and shoes (Kendon Laboratories) prior to 
entering SPF environment. Hands were washed thoroughly in a 
solution of 5% chlorhexidine gluconate (Hibitane). 
4.2.3 Breeding of Mice 
4.2.3.1 Immunocompetent Mice 
Litter sizes of BALB/c, Biozze and "Onderstepoort" mice 
ranged from 5 to 15 young. Mice were weaned at 21 days. 
Adult females were then paired with adult males of their 
respective strains to continue breeding. 
4.2.3.2 Nude Mice 
The breeding system used was that of mating heterozygous 
(nu/+) females with homozygous recessive (nu/nu) males. An 
economical ratio which resulted in maximum nude litter 
production was mating of 1 male to 3 to 4 females. Litter 
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sizes ranged from 4 to 25 mice with approximately 50% being 
nudes. The nude mice grew slowly and were smaller in size 
than heterozygous littermates (Figure 6). 
Within 3 to 5 days of birth, the homozygous nude mice were 
identified by either the absence of vibrissae or presence of 
crinkled, poorly developed vibrissae. Heterozygous males 
were immediately removed while the heterozygous females were 
left in the colony for continued breeding. The average 
weaning age was 28 days after which time the mother was 
removed and placed with a breeding mate. 
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Figure 6; Photograph of a BALB/c nude (nu/nu) and heterozygous 
immunocompetent (Nu/nu) mouse at the same age (17 days 
old) demonstrating size difference 
N = nude mouse 
I = immunocompetent mouse 
Caging 
All mice were maintained in polypropylene boxes (depth 445 rrm, 
width 280 mm, height 125 inn) with metal grills (Labotek). Each 
week cages for use in the SPF environment were washed and 
sterilized by soaking in 5% Hibitane (diluted 1 : 250) for 48 
hours. Cages were then transferred to the "trap" area for 24 
hours. A maximum of 20 mice were housed per cage. 
1 Numbering of Mice 







Higher numbers were indicated by more than one nick. 
Bedding 
Sawdust (pine and meranti wood), obtained from Baker Brothers, 
was placed in each box to a depth of approximately 2 cm to 
serve as bedding. Sawdust for nude mice was sterilized by 
autoclaving for 20 minutes at 105 kPa. Bedding was replaced 
weekly. 
6 Routine Diet 
Pelleted laboratory chow (National Pood Distributors)/ was 
provided in the food hoppers and drinking water was given by 
bottle. Both food and water were supplied ad libitum and 
changed thrice weekly. 
Food and water supplied to nude mice were autoclaved at 105 kPa 
for 20 minutes. The composition of the Standard laboratory 
chow is shown in Table I. 
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GLA ADMINISTRATION 
GLA was administered either orally or parenterally in vivo. 
For oral studies, oil enriched diets were prepared, while in 
parenteral studies GLA (Sigma) was mixed in hydrogenated 
coconut oil (HCO) and injected subcutaneously. 
Preliminary Studies Conducted to Determine the Maximum 
Tolerated Oral Fat Supplementation 
Pilot studies were conducted to determine the maximum dietary 
supplement of oil which mice would tolerate. Nude and 
immunocompetent BALB/c mice were fed standard chow supplemented 
with either 33%, 37% or 41% HCO over 42 days. HCO was used in 
these pilot studies because it was free of prostaglandin 
precursors. 
Both nude and immunocompetent mice which received 41% HCO 
showed a loss of approximately 10% body weight. 
Supplementation to levels of 37% and 31% produced no changes in 
body weight. Histopathological investigations were therefore 
conducted only in the latter two groups. Results of 
examinations performed on skin, small bowel and liver indicated 
no abnormal fatty deposits in skin and small bowel of both nude 
and immunocompetent mice consuming 33% or 37% HCO. Liver of 
nude and immunocompetent mice receiving 33% HCO were also 
devoid of abnormal fatty deposits while in the liver of both 
nude and immunocompetent mice consuming 37% HCO/ mild fatty 
changes occurred with focal necrosis in the immunocompetent 
mice. 
As pathological changes were noted only in mice consuming 37% 
H00 it was decided to use a slightly lower concentration, 
namely 35%/ in the investigations. 
1 Oil Enriched Experimental Diets 
Evening primrose oil (EPO)/ used as a source of the 
prostaglandin precursor gamma linolenic acid (GLA) (Huang 
etal./ 1982)/ was provided orally in the diet of some tumour 
bearing mice. However/ since EPO also contained linoleic 
acid (LA)/ an additional prostaglandin precursor/ isolation 
and interpretation of effects solely due to GLA were 
difficult. Sunflower seed oil (SSO) was therefore used as a 
control as it contained all fatty acids present in EPO with 
the exception of GLA (de Deckere and ten Hoor/ 1979) (Table 
II). Furthermore/ hydrogenated coconut oil (H00) which 
consisted of saturated fats only (de Deckere and ten Hoor; 
1979)/ was used as a second control (Table II). 
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During the study both nude and immunocompetent mice were fed 
one of four diets. 
(a) Standard laboratory chow or Standard chow supplemented 
with 
(b) EPO 
(c) SSO or 
(d) HCO. 
Diets were prepared as required, by the addition of 35 g 
(43 ml) of the respective oils to 65 g crushed standard chow. 
The approximate rate of food consumption was 10 g per mouse per 
day of which 3.5 g was the oil. 
Mixed diets were placed immediately in hoppers. In the SPF 
environment/ food was protected with aluminium foil against oil 
degradation by the germicidal lamp. Oil stocks were protected 
from light in dark bottles covered with alumunium foil. 
Freshly mixed diets were provided on alternate days. 
4.3.2 Parenteral Administration of GLA 
H00 which served as a control in the oral study was used as a 
solvent for parenteral administration of GLA. GLA was 
administered subcutaneously in the region of the tumour using a 
25 gauge needle (venoject). 
Control mice were injected daily with o.l ml HCO only while 
mice in the experimental group were injected daily with 0.1 ml 
HCO containing 100 ug GLA. 
TUMOUR INDUCTION 
Tumours were induced in newborn immunocompetent mice/ prior to 
full development of their immune systems/ and in weaned 
(4-6 weeks old) nude mice by the subcutaneous inoculation of 
diced tumour suspensions or cultured cells. Mice were injected 
1977). 
Volume _ length (mm) x width2(mm) 
(mm3) 2 
Tumour qrowth rates were derived from volume measurements. The 
tumours were weighed immediately following excision on a 
top - pan balance and the mass recorded in grams. 
TUMOUR EXCISION 
Depending upon the condition of the animal, the size and degree 
of invasion of the tumours and the requirements of the 
particular study (Section 5)/ mice were either sacrificed or 
anaesthetised prior to tumour excision. Mice with aggressive 
invasive tumours were sacrificed by intraperitoneal injections 
of 12 mg sodium pentobarbitone (Sagatal, Maybaker). The 
remaining mice were anaesthetised with intraperitoneal 
injections of 0.6 mg sodium pentobarbitone and 0.125 mg 
ketamine hydrochloride (ketamine diluted 1:10 in 0.9% saline). 
Following tumour removal, incisions in anaesthetised mice were 
sutured (3/8 circle 12 mm suture/ Davis and Geek). Tumours 
were placed in weighed sterile vials containing 10% formol 
saline and weights recorded. 
Tumours were processed for histopathological examination in the 
Department of Histopathology; University of Natal Medical 
School. 
7 TRANSMISSION ELECTRON MICROSCOPY 
Following excision of tumours; samples of tumour tissue were 
fixed immediately in Karnovsky's fixative (Karnovsky/ 1965) at 
pH 7.4 for 1 hour at 4°C and then postfixed in 1% osmuin 
tetroxide in cacodylate buffer at pH 7.4 for a further hour at 
4° before dehydration through increasing concentrations of 
ethanol. Samples were embedded in Araldite resin (Glauert 
etal./ 1965) and ultrathin sections were cut, stained and 
viewed as described in section 2.8.4. 
8 STATISTICAL ANALYSIS OF RESULTS 
Studies which consisted of one control and one experimental 
group with three or more mice per group were analysed 
statistically using the unpaired student's "t" test.* 
Experiments with more than one control or experimental group 
were analysed according to the Kruskal-Wallis procedure 
(Siegel, 1956). 
Statistical tests were used to compare 
1. starting tumour volumes 
2. final tumour volumes and 
3. the difference between final and initial volumes of 
control and experimental group. 
*(Tektronix 4051 computer using software written by a member of 






1 Determination of Some of the Effects of GLA 
1.1 Immunocompetent Mice 
The effects of GLA on allografts in immunocompetent mice were 
examined in 4 experiments which varied in terms of strain of 
mice/ route of fatty acid administration/ control treatment 
and duration of study. 
Tumours were established in all newborn mice as described in 
Section 4.4. The design of each of the experiments is shown 
in Table III. 
Upon tumour development/ mice were divided randomly into 
control and experimental groups. Control groups of BALB/c 
and "Onderstepoort strain" mice received standard laboratory 
chow while corresponding Biozze mice were either untreated or 
injected subcutaneously with 0.1 ml HCO. Treated groups of 
BALB/c and "Onderstepoort strain" mice received standard chow 
supplemented with 35% EPO while Biozze mice were injected 
with 0.1 ml HCO containing 100 ug GLA. 
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Table III: summary of experiments conducted to investigate the effects of EPO 
and GLA on M52B tumours growing in immunocompetent mice 
No. of mice 
inoculated 




No. of mice in 
control group 


































































2 Nude BALB/c Mice 
The effects of GLA on allografts in nude mice were assessed 
in 3 experiments which varied in terms of the number of 
animals per group, control diet and duration of study. 
In all 3 experiments/ weaned BALB/c nudes of both sexes were 
injected subcutaneously with approximately 10 M52B cells as 
described (Section 4.4). Latent periods and take rates were 
recorded. Mice which developed tumours were randomised into 
control and experimental groups. Control groups received 
either standard laboratory chow or standard chow supplemented 
with 35% HCO or 35% SSO while all experimental groups 
received standard chow supplemented with 35% EPO (Table IV). 
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Table IV: Summary of the experiments conducted to investigate the 
effects of GLA on M52B tumours growing in nude BALB/c mice 
No. of mice inoculated 
No. of mice with tumours 
Take rate 
Latent period 
No. of mice in 
control group 
No. of mice in EPO 
group 

































NUB 1 LINE 
1 investigation of some of the Effects of GLA 
1.1 Nude BALB/c Mice 
The effects of GLA on xenografts in nude mice were examined 
in 3 experiments which varied in terms of inoculum (NUB 1 
cells or NUB 1 tissue) / the number of animals per group, 
stage at which diets were started and duration of study. 
(Table v ). 
Weaned nu/nu BALB/c mice of both sexes were injected 
subcutaneously with either NUB 1 tissue or cells as described 
in Section 4.4. Mice injected with NUB 1 cells were 
randomised 5 days after inoculation, prior to tumour 
development into control and experimental groups while mice 
inoculated with NUB 1 tissue were randomised into 2 groups 
subsequent to tumour establishment. 
In addition to measuring tumour sizes, excising, weighing and 
examining histology of the tumours, incisions in nude mice of 
this study were sutured and the surviving animals observed 
for tumour recurrence. 
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Table V; Summary of the experiments conducted to investigate the effects 
of EPO on NUB 1 xenografts growing in nude BALB/c mice 
inoculum type l 
No. of mice inocu la t ed 
No. of mice with tumours 
Take r a t e 
La ten t per iod 
No. of mice in c o n t r o l 
group 
No. of mice in EPO group 
No. of days a f t e r i n o c u l a t i o n 
when d i e t was s t a r t e d 
No. of days on d i e t 
Experiment 
I 
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6.1 CHARACTERISATION OF THE M52B LINE 
6.1.1 Tumorigenicity 
Cells of the M52B line were shown to be tumorigenic in 
immunocompetent BALB/c (randombred and inbred) (Figure 7), nude 
BALB/c (Figure 8), immunocompetent Biozze and immunocompetent 
outbred ("Coderstepoort strain") mice, following subcutaneous 
inoculation of approximately 10 cells. Tumours appeared at 
the site of inoculation within 12-26 days as minute palpable 
nodules which enlarged rapidly and either regressed 
spontaneously or grew progressively to diameters of 
approximately 3.5 to 4 cm within 14 days of initial 
observation. Observed tumour latent periods/ take rates and 
remissions in different strains of mice are recorded in Table 
VI. Take rate was apparently related to the immune status of 
the host/ being highest in the nudes. Tumour remission was a 
frequent occurrence among immunocompetent mice/ though not 
observed in nudes. 
Figure 7: immunocompetent inbred BALB/c mouse bearing 
" an M52B tumour 30 days after inoculation 
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T = tumour 
Figure 8: Nude BALB/c mouse bearing an M52B tumour 
"~—•~"-—" 21 days after inoculation 
IGtitfHl 
T = tumour 
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Table VI: Tumour latent periods/ take rates and remission following 
inoculation of 106 M52B cells into BALB/c, Biozze and 
"Onderstepoort strain" mice 

























































Histopathology of Tumours 
Tumours induced in all mice were solid and generally 
encapsulated. Small tumours (average maximum diameter of 
2.5 cm) were subcutaneous and non invasive while the larger 
tumours (diameters exceeding 2.5 cm) appeared to lack a 
continuous capsule and were frequently attached to the dorsal 
skin or invaded the muscles of the abdominal wall. 
Extensive central necrosis was common in large tumours while 
smaller nodules were less affected. Each tumour had its own 
peculiar vascular pattern which consisted of a main vascular 
trunk with smaller blood vessels radiating around the tumour. 
Microscopic examination of the tumours revealed anaplastic 
sarcomas which consisted of pleomorphic; compactly arranged 
spindle cells (Figure 9) disposed in characteristic 
"herringbone" patterns (Figure 10). 
The identification of a poorly differentiated fibrosarcoma was 
favoured by the presence of pericellular reticulin (Figure 11). 
Argyrophilic fibres were evident intimately applied to the 
cytoplasmic borders of individual cells. 
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Figure 9: Photomicrograph of M52B tumour stained with haematoxylin 
and eosin to show spindle cells with large nuclei X320 
N = nuclei 
Figure 10: Photomicrograph of M52B tumour stained with haematoxylin 
and eosin showing sarcoma cells arranged in a 
"herringbone" pattern X128 
H = "herringbone" pattern 
M = mitotic figures 
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Figure 11: Section of M52B tumour stained for reticulin X400 
Af = argyrophilic fibres stained with silver nitrate 
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Figure 12: Interference photomicrograph of cultured M52B cells 
showing cytoplasmic processes X128 
Cp = cytoplasmic process 
Ultrastructural investigation of M52B cells growing in culture 
As examination of the murine sarcoma cells by light microscopy 
was limited, electron microscopic studies were carried out to 
further elucidate cell structure. 
Ultrastructural investigation of the M52B cells revealed, in 
addition to the prominent nuclei and nucleoli observed by light 
microscopy, the presence of poorly developed mitochondria, well 
developed rough endoplasmic reticulum and golgi apparati, 
myelin bodies and viral particles (Figure 14). 
Furthermore, the multilayered arrangement of cultured M52B 
cells was confirmed using transmission electron microscopy. 
The absence of desmosomes as deduced from ultrastructural 
observations supported the histological diagnosis of a 
sarcoma. 
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Figure 15: Electron micrographs of cultured M52B cells showing 
(a) structure of mitochondria and golgi apparatus X29 670 
(b) annulate lamellae and rough endoplasmic reticulum X7 2 450 
(a) 
G = golgi apparatus 
M = mitochondrion 
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(b) 
RER = rough endoplasmic r e t i c u l i 
AL = annulate lamellae 
F = fenestrae 
P = polyribosomes 
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Myelin Bodies 
Numerous "onion bulb" type myelin figures of varying sizes were 
observed in the cytoplasm of M52B cells. Such whorled 
membranous bodies often contained cytoplasm or central 
inclusions which resembled viral particles or dense bodies 
(Figure 16). 
Cell Membrane 
Activity occurred at the cell membrane as evidenced by 
phagocytosis and the formation of pinocytic vesicles. Short 
microvillous projections, most of which curved back to the 
surface were frequently observed on the cell membrane. 
viral particles 
(a) Location 
viral particles associated with sarcoma cells were 
spherical and of two apparent sizes and morphologies 
(Figure 17). Particles were observed lying freely in the 
cytoplasm (Figure 16), associated with myelin figures 
(Figure 16), scattered in the intercellular (Figure 18a) 
and extracellular (Figure 18b) spaces, budding from the 
cell membrane (Figure 19) or apparently being liberated via 
microvilli (Figure 17 - vi). 
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Figure 16: Electron micrograph of cultured M52B cell showing virus 
like particle in myelin figure and in the cytoplasm 
X93 150 
&:* 
v 1 - virus like particle in myelin figure 
v 2 - virus like particle free in cytoplasm 
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Figure 18; Electron micrographs showing cultured M52B cells with 
(a) an intercellular (xlOO 000) and 
(b) extracellular associated virus particles (X29 67o) 
(a) 




v = extracellular virus particles 
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v(b) Size and Morphology 
The approximate diameters of the putative viruses were 95 nm 
and 47 nm respectively with the former having core diameters of 
approximately 47 nm (refer to Figure 17). The cores of the 
latter particle could not be distinguished from their 
envelopes. Therefore/ the viral particles we*-e categorised 
into large enveloped particles and small virus particles which 
apparently lacked an envelope. However; differences in core 
density of the enveloped virus particles were observed. 
Figures 18a and 20 show large enveloped particles with electron 
lucent and electron dense cores respectively. Figure 21 was 
compiled to demonstrate the different sizes and morphologies of 
viral particles present in the M52B cell. 
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Figure 20: Electron micrograph of cultured M52B cells showing a large 
extracellular virus particle with an electron dense centre 
X93 150 
v = virus with electron dense core 
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) The Budding Process 
Numerous budding particles seen associated with the cell 
membrane led to the assumption that budding was involved in 
viral release. 
Figure 16 represents the stage just prior to budding where 
single membrane bound virus particles occur either in the 
cytoplasm or myelin figures of M52B cells. In the postulated 
second stage (Figure 22a) these virus particles become 
associated with the cell membrane and thus acquire a second 
membrane. Figure 22b represents an advanced phase of (a). 
Figure 19 shows that stage of budding just prior to the virus 
becoming an extracellular particle/ while Figure 23 represents 
the product of budding - a double membrane bound virus particle 
outside the cell membrane. 
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Figure 22: Electron micrograph of cultured M52B cells showing an 
early stage (a) and late stage (b) of virus budding 
X57 500 
a - in the early stages of budding the core of the virus may push 
against the cell membrane. The second membrane which encloses 
the virus particle may be attained during this stage. 
b - in the advanced stage of a, more of the viral core is seen 
enclosed by a double membrane 
81 
Figure 23; An electron micrograph showing an extracellular virus 
particle (v) released by budding from an M52B cell. The 
virus particle consists of a core circumscribed by a 
double membrane X227 750 
m^JoBrj 
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Figure 24; Appearance of dense cultures of M52B cells 48 hours after 
addition of a single dose of GLA (0 / 50 and lOOug/ml). 
May-Grunvva Id/Giem sa 
ug / ml GLA 
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Figure 25: Appearance of dense cultures of M52B CELLS 48 hours after 
-—-—-—-— addition of multiple doses of GLA ( 0 - 5 0 ug/ml). 
May-Grunwald/Giemsa 
ug / ml GLA 
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Figure 26: Electron micrograph of control M52B cells growing in 
culture X19 750 
RER = Rough endoplasmic reticulum 
EFFECTS OF GLA ON PROSTAGLANDIN SYNTHESIS 
The amounts of PGE and PGF released into the medium by GLA 
treated and control M52B cultures are recorded in Table IX. 
Full data on PG calculations appear in Appendix 1. The results 
are reported as PGE and PGF and no distinction is drawn between 
the 1 and 2 series since anti PGE2 antibody had a 20% 
cross-reactivity with PGE-i at 50% inhibition of maximum binding 
and PGF2Q; antibody had a 10% cross reactivity with PGF-,( 
(Norman et al., 1981; Norman and Joubert, 1982). Cells treated 
with GLA released more PGE and PGF into the medium than did 
controls. However, analysis of results using the Mann Whitney 
U test (Siegel, 1956) showed these differences to be 
statistically non significant for both PGE and PGF on 
two-tailed tests. 
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Table IX: Amounts of prostaglandins (PGs) released into the 
medium by control and GLA treated M52B cultures 












0.18 - 0.64 
0. 
0.02 
0.01 - 0.05 
GLA treated 
0.59 
0.34 - 0.91 
08 
0.03 
0.01 - 0.05 
0.56 
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7.1 EFFECTS OF GLA ON IMMUNOCOMPETENT MICE BEARING M52B TUMOURS 
7.1.1 Effects of oral GLA on Randombred BALB/c Mice 
Tumour take rates, latent periods and remissions observed in 
the two experiments in this study are recorded in Table VI 
(Section 5.1.1.1). Full data on tumour measurements appear in 
Appendix 2.1 and Appendix 2.2. 
Due to the very small numbers of mice per group remaining at 
the end of the studies, results of the experiments were not 
statistically analysed and are therefore represented as tumour 
volumes only (Tables Xa and xb). No conclusions can be drawn 
from these studies. 
7.1.2 Effects of Oral GLA on Inbred BALB/c Mice 
As inoculation of inbred immunocompetent BALB/c mice was 
followed by 100% tumour remission within 25 days, completion of 
this study was not possible (Section 5.1.1.1). 
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Table Xa: Mean volumes and SEM of M52B tumours in randombred, 



















































Table xb: Mean volumes and SEM of M52B tumours in randombred/ immunocompetent 






















































3 Effects of Parenteral GLA on Inbred Biozze mice 
Results of the experiment in which mice were either untreated 
or injected subcutaneously with GLA in HCO or HCO only are 
included in Appendix 3, summarised in Table XI and graphically 
represented in Figure 28. 
Due to high rates of tumour remission and subsequent small 
numbers of animals in this study, no statistical test could be 
used to analyse these results. Thus, it is not possible to 
make any inferences from this experiment on the effects of 
parenteral GLA on the growth of M52B tumours in inbred 
immunocompetent Biozze mice. 
4 Effects of Oral GLA on Outbred mice of the "onderstepoort 
strain" 
The effects of oral GLA on M52B tumours in outbred mice are 
included in Appendix 4, summarised in Table XII and graphically 
represented in Figure 29. The results were not analysed 
statistically because of the small number of mice remaining in 
the control group at the end of the study. 
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Table XI: Summary of M52B tumour volumes prior to and following 
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Figure 28: volumes of M52B tumours in inbred, immunocompetent Biozze mice 
injected with nothing, GLA in HCO or HCO only 
GLA+HCO (n = 5) 
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Figure 29; volumes of M52B tumours in immunocompetent outbred mice of 






























— CONTROL (n=2) 
— EPO (n = 7) 
3 4 5 6 7 8 9 1 0 11 
NO. OF DAYS AFTER BEGINNING OF TREATMENT 
12 13 14 
103 
Figure 3Qa: volumes of M52B tumours in nude BALB/c mice consuming 
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Table Xlllb; Summary of M52B tumour volumes in nude BALB/c mice prior 












































•Unpaired student's "t" test (2 tailed) 
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Figure 30b: volunes of M52B tumours in nude BALB/c mice consuming 
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Table XIIIC; Summary of M52B tumour volumes in nude BALB/c mice prior 











































•Unpaired student's "t" test (2 tailed) 
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Figure 3Qc; volumes of M52B tumours in nude BALB/c mice consuming either normal 
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TRANSMISSION ELECTRON MICROSCOPY OF CONTROL AND EPO TREATED 
MURINE SARCOMA TUMOURS 
Although oral treatment with EPO did not significantly affect 
the growth of M52B tumours in nude mice; ultrastructural 
examinations were still performed on these tumours to assess 
for any morphological changes. Figure 31 is an electron 
micrograph of an untreated M52B tumour with no excess lipid 
accumulation and non distended endoplasmic reticulum. Electron 
microscopic examination of EPO treated M52B tumours revealed 
the presence of lipid droplets and numerous swollen endoplasmic 
reticulum in most cells (Figure 32a). As virus particles were 
observed in all samples the oil had no apparent effect on virus 
production (Figure 32b). 
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Figure 31; Electron micrograph of an untreated murine sarcoma growing 
in a nude mouse X41 250 
RER = rough endoplasmic reticulum 
110 
Figure 32a: Electron micrograph of a murine sarcoma growing in a nude 
————— mouse treated with oral EPO X40 600 
RER = swollen rough endoplasmic reticulum 
L = lipid 
Ill 
Figure 32b: Electron micrograph of a murine sarcoma growing in a nude 
mouse treated with oral EPO X41 250 
v = virus particles 
L = lipid 
RER = swollen rough endoplasmic reticulum 
EFFECTS OF ORAL GLA ON NUDE BALB/c MICE BEARING NUB 1 TUMOURS 
Results of the three experiments conducted to assess the 
effects of oral GLA on nude BALB/c mice bearing NUB 1 
xenografts are summarised in Table Xiva / b, c and d. The 
unpaired student's "t" test vas used to compare the difference 
in initial tumour volumes between control and experimental 
groups. 
Experiment 1 was a pilot study in which small numbers of 
animals were used. Results of this study were therefore not 
analysed statistically and thus no inferences can be made from 
this experiment (Table xiva, Figure 33a and Appendix 6.1). 
In experiment 2, although the study was concluded after 30 
days; for statistical purposes/ analysis of results was carried 
out after 20 days treatment as the number of mice per group 
decreased after this period due to animal deaths which resulted 
from massive tumour invasion. As the initial volumes in the 
control and experimental group differed significantly at the 
beginning of the experiment (Table xivb)/ percent increase in 
volume over the experimental 20 days was assessed in this study 
(Table xlvc). Analysis of results using the unpaired student's 
"t" test showed the difference in percent increase in final 
tumour volumes between control and experimental groups to be 
statistically non significant (Table Xivc). Figure 33b is a 
graphical representation of the growth of NUB 1 xenografts 
during the experiment (Appendix 6.2). 
The third experiment, although large numbers of animals were 
used, statistical analysis of results showed that oral EPO had 
no signifcant influence on tumour growth (Table XlVd, Figure 
33c and Appendix 6.3). 
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Figure 33a: volumes of NUB 1 tumours in nude BALB/c mice consuming 















CONTROL (n = 2) 
EPO (n=4) 
T -
4 6 8 10 12 14 16 
— i — 
18 
NO. OF DAYS AFTER BEGINNING OF TREATMENT 
116 
Table xivb: Summary of NUB 1 tumour volumes in nude BALB/c mice prior 
to treatment with oral EPO 
Experiment 2 
Before 



















•Unpaired student's "t" test (2 tailed) 
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Table xivc: Summary of percent increase in NUB 1 tumour volumes in 
nude BALB/c mice following treatment with oral EPO 
Experiment 2 
Percen t 






















•Unpaired student's "t" test (2 tailed) 
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Figure 33b: volumes of NUB 1 tumours in nude BALB/c mice consuming 
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Table Xivd; Summary of NUB 1 tumour volumes in nude BALB/c mice prior 
to and following treatment with oral EPO 
Experiment 3 
Before 
t r e a t m e n t 
21 d a y s 
a f t e r 
t r e a t m e n t 
i n c r e a s e i n 
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1O94.0 
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•unpaired student's "t" test (2 tailed) 
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Figure 33c; volumes of NUB 1 tumours in nude BALB/c mice consuming 
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7.4.1 Tumour Recurrence 
Encapsulated NUB 1 xenografts were removed from control and 
treated mice in an attempt to investigate any differences in 
incidence of tumour recurrence. However, recurrence was noted 
in both control and treated animals; an observation which 
could be attributed to the fact that the entire tumour may not 
have been excised. Although recurrence occurred within two 
weeks of excision in 1 out of 6 control and 3 out of 6 EPO mice 
in Experiment 1 and in 1 out of 4 EPO mice in Experiment 2, 
this phenomenon was not observed in Experiment 3. 
7.5 SUMMARY OF IN VIVO RESULTS 
GLA, administered orally in the form of EPO was found to have 
(1) no significant effect on the growth of M52B tumours in 
nude mice. 
(2) no significant effect on NUB 1 tumours in nude mice. 
Unfortunately, despite numerous attempts to grow the M52B cells 
in immunocompetent mice of various strains, most tumours 
regressed spontaneously. Consequently, the numbers of animals 
remaining in each group were too small to draw any real 




Although growth of M52B cells in vitro was clearly inhibited by 
the addition of GLA to the culture medium, growth of solid M52B 
sarcomas in vivo in immunodeficient mice was apparently 
unaffected by dietary GLA in the form of EPO. Growth of NUB 1 
xenografts in immunodeficient mice was also unaffected by 
dietary EPO. 
8.1 EFFECTS OF GLA IN VITRO 
The inhibitory and toxic effects of GLA on growth of the 
sarcoma cells and non malignant fibroblasts in vitro were 
similar to those of other studies using human oesophageal 
carcinoma (Booyens etal., 1984a: Leary etal., 1982)/ breast 
carcinoma (Begin etal., 1985; Robinson and Botha, 1985; 
Robinson etal., 1985), lung carcinoma (Begin etal., 1985), 
osteogenic sarcoma (Booyens etal., 1984a; 1984c), hepatoma 
(Booyens et al., 1984b; Dippenaar et_al., 1982b), mouse 
melanoma (Dippenaar et al., 1982a); and benign LLCMK monkey 
kidney cells (Booyens et al., 1984b). The concentration 
dependant and time related inhibition of growth reported in all 
these studies was also confirmed in the present study using 
M52B cells. Furthermore, the effects of GLA on cell growth 
were related to the absolute cell number as the fatty acid was 
found to produce more pronounced effects in less dense 
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cultures/ presumably as more GLA was available per cell. 
Despite this, each cell line investigated has been reported to 
respond to a slightly different extent with respect to changes 
in morphology and growth inhibition/ to equivalent doses of 
GLA. These apparent differences could be related to factors 
such as structure and function of the cells, culture 
environment/ the mitotic rate/ number and size of cells (Leary 
et al./ 1982). 
8.1.1 proposed mechanism/s of action of GLA in vitro 
Although exogenous GLA/ in doses ranging from 0/05 to 200 ug/ml 
has been reported to consistently inhibit the growth of 
malignant cells in vitro/ the exact mechanism/s of action is 
unknown. However, many workers (Booyens et al., 1984a,1984b, 
1984c; Dippenaar et al., 1982a, 1982b; Leary et al., 1982) have 
assumed that the observed effects of GLA may be due to the 
fatty acid bypassing a deficient A 6 desaturase and 
consequently serving as substrate for PGE-, synthesis, as 
previously proposed (Horrobin, 1980a). If the effects of GLA 
were mediated mainly in this way, then non malignant cells 
which are presumed to have a functional A 6 desaturase and 
therefore an endogenous source of GLA, might be unaffected or 
respond differently to the addition of exogenous GLA. While 
GLA at a concentration of 10 ug/ml has been reported to be 
without effect on the growth of cultured normal bovine kidney 
MDBK cells (Dippenaar et al., 1982a), in another study using 
the same concentration of the fatty acid, it was found to 
inhibit proliferation of cultured benign LLCMK cells (Booyens 
et al., 1984b). In the present study using non malignant 
fibroblasts, exposure to high concentrations of GLA (> 50 
ug/ml) also inhibited cell growth. The inhibitory effects of 
GLA on growth of non malignant cells may imply that the actions 
of the fatty acid are not exclusively due to bypassing a 
deficient A6 desaturase. In fact, other polyunsaturated as 
well as saturated fatty acids have also been reported to 
inhibit growth of non malignant human foreskin fibroblasts and 
guinea pig smooth muscle (Huttner et al., 1977), rabbit smooth 
muscle (Smith et al., 1984) and epithelial cells of rat jejunum 
(Petry et al., 1984). A finding which casts further doubt upon 
Horrobin's proposal is the reported effect of LA on growth of 
malignant cells. Since such cells are presumed to be deficient 
in A 6 desaturase and therefore unable to metabolise LA, this 
fatty acid would be expected to have no effect on malignant 
cell proliferation. With the exception of a single study in 
which 10 ug/ml LA was found to be without effect on growth of 
cultured human hepatoma cells (Booyens et al., 1984b), in other 
studies using different concentrations of the fatty acid, 
results to the contrary have been reported. For example, LA at 
concentrations of 1 uq/ml and 5 ug/ml has been found to 
augment growth of cultured mammary (Kidwell et al., 1978; 
Wicha et al., 1979) and ascites tumour XS 63.5 (Holley et al., 
1974) cells respectively while at 20 ug/ml and 50 ug/ml it has 
been shown to inhibit proliferation of cultured human 
osteogenic sarcoma (Booyens et al., 1984a; 1984c); breast and 
lung carcinoma (Begin et al.; 1985) and; human breast and 
oesophageal carcinoma (Robinson etal.,1985) respectively. 
Thus; since LA and GLA have generally been reported to produce 
effects inconsistent with the deficient A6 desaturase theory, 
it is possible that effects observed with both these fatty 
acids might have been via a non-specific fat-effect. In fact, 
prior to cell death, both malignant and non malignant cells 
treated with GLA in the present study accumulated paranuclear 
granules which were lipid in nature. The cell death may 
therefore have been secondary to a fat overload. In addition; 
the accumulation of lipid by these cells increased with 
increasing concentrations of the fatty acid. However, other 
workers who reported lipid accumulation in GLA treated human 
mammary (Robinson and Botha, 1985) and oesophageal (Robinson 
et al., 1985) carcinoma cells, found equivalent doses of LA 
and DGLA to produce fewer or no obvious lipid deposits and to 
affect growth of these cells to a lesser extent. Thus, 
inhibition of growth of these fatty acid treated cells cannot 
be solely attributed to cellular lipid accumulation. It is 
possible, however, that the non-specific inhibition of growth 
by the fatty acids may have been due to altered metabolism or 
cell membrane structure brought about by exposure of neoplastic 
cells to excess exogenous unsaturated fatty acids (Carroll/ 
1981: vitale and Broitman, 1981; Welsch and Aylsworth/ 1983). 
Incorporation of cis-unsaturated fatty acids into the plasma 
membranes of malignant cells may render these structures more 
susceptible to changes in fluidity (Abbas etal., 1982). 
Alternatively, the inhibition of cell growth by GLA in this 
study, and by DGLA and LA in other studies (Robinson and Botha, 
1985: Robinson etal., 1985) may have resulted from a detergent 
effect, as these fatty acids were dissolved in Na2003 hence 
forming soaps. However, the fact that the oleic acid-soap, 
which is known to lower surface tension more than the palmitic 
and stearic acid soaps (Singleton, 1960), stimulated cell 
proliferation in non malignant smooth muscle cultures at high 
concentrations of 90 uM while equivalent concentrations of the 
latter two fatty acids persistently inhibited growth, casts 
doubt upon the assumption that these and other fatty acids are 
influencing cell growth purely via a detergent effect (Huttner 
etal., 1978). More recently, workers (Begin et al., 1985; 
Smith et al., 1984) also indicated that the inhibitory effects 
of polyunsaturated fats on growth of malignant cells in vitro 
may be related to lipid peroxide production. 
Despite the many possible suggestions that have been offered to 
explain the mechanism of action of GLA on cell growth, there 
appears to be much support for the proposal that provision of 
GLA to malignant cells increases PGE synthesis and subsequently 
"normalises" cell growth. 
Indeed, there is considerable direct and indirect evidence, 
involving the use of PG synthetase inhibitors, and cAMP, that 
exogenous PGE-. inhibits the growth of malignant cells 
(Section 1.2.2.1). However, exogenous PGE2 has also been 
reported to retard malignant cell growth (Section 1.2.2.1). 
Thus, since GLA is a precursor of both PGEj and PGE2 (Horrobin, 
1980a), it is possible that PGE2 may also have contributed to 
the effect of GLA upon cell growth. The PG assay performed in 
the present study showed that although PGE levels rose after 
exposure of M52B cells to GLA, this increase was not 
statistically significant. In addition, it was not possible to 
determine whether the elevated PGE levels represented PGE-, or 
PGE2 since anti PGE2 and anti PGF2Q, antibodies cross reacted 
significantly with PGET and PGF2Q, respectively (Norman and 
Joubert, 1982; Norman et al., 1981). However, the small 
increase in PGE recorded in this study may imply that the 
actions of GLA are partially mediated by PGE, but the extent to 
which PGE-, and PGE2 may have been involved in inhibiting the 
growth of M52B cells could not be determined. If the actions 
of GLA were in fact mediated by increased synthesis of PGE-, 
then DGLA which is a metabolite of GLA and the immediate 
precursor to PGE-. (Horrobin, 1980b), would also be expected to 
inhibit cell proliferation. While DGLA at concentrations of 
100 and 200 ug/ml has been reported to produce such an effect, 
though to a lesser extent than equal doses of GLA, 
concentrations of 20 to 50 ug/ml DGLA stimulated growth of 
malignant cells (Robinson and Botha, 1985). These findings 
therefore do not support the suggestion that PGE-, is the sole 
mediator of the effects observed with GLA. 
In summary, there is considerable evidence that exogenous fatty 
acids may generally exert a non-specific fat-effect on a wide 
range of non malignant and malignant cells in vitro. While 
this is particularly so at high doses (> 50 ug/ml), the exact 
mechanism/s of the effects observed with low concentrations 
(< 50 ug/ml) of certain of the fatty acids remain obscure. In 
particular, while effects of GLA may in part be mediated via a 
fat overload, it is possible that provision of deficient 
precursor for PGE synthesis may also play a role. 
Since GLA inhibited the growth of M52B cells in vitro, further 
studies were conducted to determine whether such an effect 
could be reproduced in vivo. However, in vivo models are 
clearly different from in vitro systems in many ways. Cells in 
solid tumours exist in a variety of environments with respect 
to O2 and <X>2 concentrations, nutrient availability and pH, 
while such factors are controlled for optimum growth in culture 
(Rockwell, 1977). Furthermore, the growth of tumours in vivo 
is influenced by the host's immune system (Ziegler, 1982), 
while cultured cells are free from such influence. The effects 
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of drugs in vivo also depend on the vascularity of the tumour, 
transport of the drug to and within the tumour and metabolism 
of the drug by the host. Though the influence of these factors 
in vivo does not permit direct comparison between in vitro and 
in vivo studies, it is essential to assess the effects of drugs 
in in vivo animal models prior to any use in humans to 
determine not only efficacy but also safety of the drug. 
8.2 EFFECTS OF GLA IN VIVO 
• — — 
Findings of the present in vivo investigation using M52B and 
NUB 1 tumours were generally consistent with those of other 
workers who failed to reproduce the in vitro effects of GLA in 
vivo. For example, the growth of human tumour xenografts in 
immunocompetent rats (Booyens and Koenig, 1984) and 
immunodeficient nude mice (Botha etal., 1983) has been 
reported to be unaffected by dietary EPO and subcutaneous 
administration of GLA respectively. It is possible that in 
studies with nude mice, the immune status of the animal may 
have influenced the results (Botha etal., 1983). There is 
indeed both in vitro and in vivo evidence which indicates that 
exogenous saturated and polyunsaturated fatty acids, in 
particular LA, linolenic acid and AA are immunosuppressive and 
consequently promote tumour growth (Section 1.2.2.1). Many 
workers have further indicated that since LA, GLA and AA are PG 
precursors, the immunosuppression produced by these fatty acids 
may be mediated by synthesis of PGs (Section 1.2.2.1). Thus, 
since the oil containing diets used in the present study were 
rich in either polyunsaturated fat and PG precursors (EPO and 
SSO) or saturated fat (HCO) / it was possible that these oils 
which are known to affect the immune system might have produced 
variable effects in animals of differing immune status. 
Unfortunately/ only results obtained using immunodeficient mice 
were analysed statistically in the present study and these 
indicate that neither EPO; SSO nor HCO had any significant 
effect on growth of tumours in vivo. Although studies were 
conducted on various strains of immunocompetent mice, little 
can be inferred from these investigations as results were based 
on data collected from small numbers of animals. This was 
unavoidable due to the occurrence of spontaneous tumour 
remission in large numbers of animals. 
In addition to the obvious differences between in vitro and in 
vivo environments, other possible factors which may contribute 
to the difference in effects of GLA observed in these two 
systems include the following. While GLA was administered in 
its pure form in vitro, in most of the in vivo experiments the 
fatty acid was administered in the form of EPO. Since the 
other fatty acids present in EPO e.g. LA, oleic, myristic, 
palmitic and stearic acid have been reported to affect the 
endocrine system and the fluidity of cell membranes, it is 
possible that these additional fatty acids may have masked the 
effects of GLA (Section 1.2.2.1). 
Furthermore, many workers have reported a positive association 
between dietary LA and the growth of mammary (Carroll and Khor, 
1971: Hopkins etal., 1981: Rao and Aylsworth, 1976: Tinsley 
etal., 1981), colon, skin, hepatic, pulmonary and pancreatic 
cancers. However, such an association has not been reported in 
sarcoma bearing animals (Birt etal., 1981: Carroll and Khor, 
1975; Hopkins etal., 1978; Reddy et al., 1977: Watson and 
Mellanby, 1930). If dietary LA does in fact promote growth of 
tumours in vivo, then the apparent lack of effect of EPO on 
both the carcinomas and sarcomas in this study may be explained 
by a neutralization of the effects of GLA by LA. In addition, 
Booyens and Katzeff (1985) have recently reported that oleic 
acid promotes growth of malignant cells in vitro. They have 
therefore suggested that the lack of effect of GLA containing 
diets in vivo may be due to the influence of oleic acid. It 
seems unlikely, however, that this fatty acid would have 
exerted a significant effect on tumour growth in the present 
study as EPO only contains 8.8% oleic acid. 
Thirdly, the lack of effect of GLA on "tumour growth in vivo may 
have been related to the fact that treatment was initiated on 
well established tumours. However, the influence of tumour 
size on the effects of the fatty acid would not appear to be 
significant as prophylactic administration of GLA has also been 
reported to be without effect on tumour growth (Botha et al., 
1983). 
A fourth possibility is that the direct administration of GLA 
to M52B cells in vitro which resulted in intracellular lipid 
accumulation may have been the cause of cell death. In vivo 
however, the supplemented fatty acid may have been metabolised 
prior to reaching the tumour site. Although subcutaneous 
administration of GLA could be expected to deliver more of the 
fatty acid to the site of the tumour than oral administration 
and consequently be more likely to inhibit tumour growth/ such 
results were not obtained in the study of Botha etal. (1983) 
using this route. However, Ghayur and Horrobin (1981) showed 
that tumour growth was inhibited by subcutaneous administration 
of EPO to rats bearing mammary allografts. In both the present 
study and in that of Botha etal. (1983) in which GLA was 
administered parenterally, fat deposits were observed at the 
site of injection of the fatty acid. This complicated 
assessment of tumour sizes. Presumably, Ghayur and Horrobin 
(1981) did not encounter this problem as smaller volumes were 
administered to larger hosts i.e. rats. Furthermore, rats have 
been reported to have a more active A 5 desaturase than mice 
(Stone etal., 1979) which allows them to convert exogenous GLA 
preferentially to PGE2. Since PGE2 has been shown to inhibit 
tumour growth in vivo (Section 1.2.2.1), it is possible that 
the inhibition of growth reported by Ghayur and Horrobin 
following administration of EPO may be related to PGE2 
synthesis. Their findings may therefore reinforce the argument 
put forward earlier that PGE-, alone is probably not responsible 
for the inhibitory effects of GLA upon the growth of malignant 
cells. 
In addition/ as already discussed; it is possible that the 
effects of EPO on allograft growth observed by Ghayur and 
Horrobin may have been related to the fact that the rats used 
in their study were immunocompetent while the mice used in the 
present study and in that of Botha etal., (1983) were 
immunodeficient. 
Another possible reason for the difference in responses of 
allografts to subcutaneous GLA may be related to the fact that 
the allograft in the present study was a sarcoma while that 
used by Ghayur and Horrobin (1981) was a hormone dependant 
(Bradley/ 1976) mammary carcinoma. Thus/ the inhibition of 
tumour growth produced by GLA in the latter study may have been 
due to alterations in the hormonal environment. In fact/ there 
is evidence which indicates that fatty acids increase prolactin 
secretion (Chan et al./ 1975/ 1977; Welsch and Aylsworth, 1983; 
Welsch and Nagasawa; 1977) and hypersecretion of this hormone 
has been reported to inhibit the growth of many mammary tumours 
(Welsch and Aylsworth, 1983; Welsch and Nagasawa / 1977) 
including the R3230AC rat mammary tumour used by Ghayur and 
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APPENDIX 1 
PG PRODUCTION (CORRECTED FOR PROTEIN CONTENT OF CELLS) 
BY CONTROL AND GLA TREATED M52B CELLS 
PGE 
PGF 






































APPENDIX 2 . 1 
MEASUREMENTS OF M52B TUMOURS IN RANDOMBRED IMMUNOCOMPETENT BALB/c 








































MEASUREMENTS OF M52B TUMOURS IN RANDOMBRED IMMUNOCOMPETENT BALB/c 
MICE CONSUMING EITHER NORMAL CHOW OR EPO SUPPLEMENTED CHOW 
Experiment 1 
NO. o f 
days 
f o l l o w i n g 






6 . 3 
9 . 4 
1 2 . 6 




6 . 3 
9 . 4 
1 2 . 6 
1 4 . 5 
V o } . 
(mm ) 
1 2 5 . 1 
4 1 5 . 3 
1 0 0 0 . 2 





2 0 . 6 1 5 . 4 
2 4 . 0 2 3 . 4 
2 4 . 9 2 4 . 4 
25.O 2 4 . 9 
measurements 
EPO (n=4) 
V o l . 
( n n 3 ) 
2 4 4 2 . 7 
6 5 7 0 . 7 
7 4 1 2 . 2 
7 7 5 0 . 1 
L 
(mm) 
2 4 . 1 
2 5 . 1 
2 6 . 2 
2 6 . 9 
3 
9 
2 0 . 3 
2 3 . 3 
2 4 . 9 
2 1 . 9 
V o l . 
(mm3) 
4 9 6 5 . 7 
6 8 1 3 . 3 
8 1 2 2 . 1 
6 4 5 0 . 8 
L 
( 
2 4 . 7 
1 0 . 0 
3 0 . 0 
3 6 . 3 
3 9 . 3 

















MEASUREMENTS OF M52B TUMOURS IN RANDOMBRED IMMUNOCOMPETENT BALB/c 






















































11.0 11.0 665.5 




MEASUREMENTS OF M52B TUMOURS IN RANDOMBRED IMMUNOCOMPETENT BALB/c 





























































MEASUREMENTS OF M52B TUMOURS IN INBRED IMMUNOCOMPETENT BIOZZE MICE 













4 . 0 2 .5 
9 . 0 7 .0 
spontaneous 
r eg re s s ion 









3 .5 3 .5 
6 .0 5.0 
6 .0 5.0 
6 .0 4 . 0 
spontan< 












12.0 6 .0 
9 .0 6 .0 
11.0 7 .0 
9 .0 8 .0 
12.0 6 .0 
10.0 9 .0 
12.0 8 .0 
11.0 8 .0 













4 . 0 3.5 
3.5 3.5 











8.0 6 .0 











MEASUREMENTS OF M52B TUMOURS IN INBRED IMMUNOCOMPETENT BIOZZE MICE 

















































































6.0 6.0 108.0 
spontaneous 
regression 
MEASUREMENTS OF M52B TUMOURS IN INBRED IMMUNOCOMPETENT BIOZZE MICE 
INJECTED WITH NOTHING, GLA IN HCO OR HCO ONLY 
No. o f 
days 
a f t e r 
t r e a t m e n t 
Tumour measurements 
Experimental (GLA+HOO) n=8 
V o l . 
(ran3) 
V o l . 
(mm3) 
V o l . 
(mm3) 
v o l . 
(mm3) 
V o l . 
(ran3) 














L 6 L e 
(ran) 
10 
3 . 5 3 . 0 
1 8 . 0 8 . 0 
1 8 . 0 R.O 
1 9 . 0 B.O 
1 9 . 0 8 . 0 
1 5 . 8 
5 7 6 . 0 
5 7 6 . 0 
6 0 8 . 0 
6 0 8 . 0 
2 0 . 0 1 5 . 0 
23.0 20.0 
2 5 . 0 21.O 
2 5 . 0 2 1 . 0 
25.0 22.0 
2250.0 
4 6 0 0 . 0 
5 5 1 2 . 5 
5 5 1 2 . 5 
6 0 5 0 . 0 





1 0 . 0 1 0 . 0 
1 8 . 0 18.O 
24.0 20.0 
2 4 . 0 2 1 . 0 
2 6 . 0 2 4 . 0 
5 0 0 . 0 
1 7 6 4 . 0 
4800.0 
5 2 9 2 . 0 
7488.0 
6 . 0 5 . 0 
9 . 0 7 . 0 
9.0 7.0 
1 8 . 0 1 8 . 0 
22.O 22.0 
75.0 
2 2 0 . 5 
2 2 0 . 5 
2 9 1 6 . 0 
5324.O 
6 . 5 6 . 5 
lO.O 8 . 0 
1 1 . 0 lO.O 
2 3 . 0 1 3 . 0 
3 3 . 0 1 8 . 0 
1 3 7 . 3 
320.0 
5 5 0 . 0 
1 9 4 3 . 5 
5346 .O 




MEASUREMENTS OF M52B TUMOURS IN IMMUNOCOMPETENT OUTBRED "ONDERSTEPOORT 









































































v o l , 
(mm5) 
650.0 
MEASUREMENTS OF M52B TUMOURS IN IMMUNOCOMPETENT OUTBRED "ONDERSTEPOORT 

















1O.0 28 .0 









8 .0 7 .0 
25.0 17.0 
8 .0 7.0 
29.0 22.0 
lO.O 8 .0 


























41 .0 19.0 
44 .0 22 .0 
46.0 21.0 









30 .0 24 .0 
31.0 24.0 




























37 .0 24.0 













APPENDIX 5 . 1 
MEASUREMENTS OF M52B TUMOURS IN NUDE BALB/c MICE CONSUMING 
EPO, SSO OR HCO SUPPLEMENTED CHOW; OR NORMAL CHOW 
Experiment 1 
No. o f 
days 
f o l l o v d n g 








Mass o f 
tumours 
( g ) 
Tumour measurements 




6 . 5 6 . 5 
5 . 4 5 . 2 
2 0 . 0 7 . 5 
2 0 . 0 9 . 0 
2 4 . 5 lO.O 
2 4 . 0 12 .O 
1 3 . 8 1 3 . 0 
2 6 . 8 1 3 . 0 
2 4 . 6 1 5 . 7 
3 3 . 0 1 4 . 0 
2 7 . 5 2 1 . 5 
3 3 . 0 1 7 . 0 
4 4 . 0 3 1 . 0 
4 9 . 0 34 .O 
V o l , 
(mm ) 
7 7 2 . 8 
2035 .O 
5 1 5 8 . 7 
6 2 6 5 . 8 
1 1 1 2 4 . 4 
2 1 1 4 2 . 0 
2 8 3 2 2 . 0 




9 . 0 8 . 0 
1 1 . 0 1 1 . 0 
1 7 . 0 1 4 . 5 
1 7 . 7 1 7 . 5 
2 1 . 8 2 0 . 5 
2 6 . 5 2 6 . 5 
3 0 . 0 3 0 . 0 
V o l , 
(ran ) 
2 8 8 . 0 
6 6 5 . 5 
1 7 8 7 . 2 
2 7 1 0 . 3 
4 5 8 0 . 7 
9 3 0 4 . 8 
135CO.O 




1 2 . 0 9 . 5 
1 4 . 7 1 3 . 0 
9 . 0 7 . 0 
5 . 5 5 . 5 
1 8 . 3 16.O 
2 6 . 8 2 2 . 0 
2 1 . 5 1 9 . 0 
2 8 . 5 2 5 . 0 
2 6 . 5 2 2 . 0 
3 8 . 5 2 6 . 5 
2 7 . 5 2 7 . 5 
3 8 . 5 2 9 . 0 
2 7 . 5 2 7 . 5 
3 8 . 5 3 0 . 0 
V o l , 
(mm ) 
5 4 1 . 5 
1 5 4 5 . 8 
8 8 2 8 . 0 
12787.O 
1 9 9 3 1 . 3 
2 6 5 8 7 . 7 
2 7 7 2 3 . 4 




lO.O 1 0 . 0 
1 3 . 0 1 1 . 0 
1 4 . 7 1 0 . 0 
1 2 . 5 1 1 . 2 
1 8 . 2 1 2 . 7 
1 5 . 5 1 1 . 0 
1 6 . 0 1 2 . 0 
V o l . 
(mm3) 
5 0 0 . 0 
7 8 6 . 5 
7 3 5 . 0 
784 .O 
1 4 6 7 . 7 
9 3 7 . 8 
1 1 5 2 . 0 




1 . 0 1 . 0 
4 . 5 4 . 5 
4 . 5 4 . 5 
7 . 0 6 . 4 
8 . 6 8 . 6 
9 . 5 9 . 5 
1 0 . 0 1 0 . 0 
V o l . 
(mm3) 
0 . 5 
4 5 . 6 
4 5 . 6 
1 4 3 . 4 
3 1 8 . 0 
4 2 8 . 7 
5 0 0 . 0 
0 . 2 7 
Mean v o l . 
(nm3) 
n=5 
4 2 0 . 6 
1 0 1 5 . 7 
3 3 1 0 . 9 
4 5 3 8 . 1 
7 4 8 4 . 4 
1 1 6 8 0 . 2 
1 4 2 3 9 . 5 
SEM 
1 3 0 . 2 
3 4 9 . 0 
1 6 3 5 . 1 
2 3 2 1 . 4 
3 6 3 4 . 3 
5 2 8 8 . 7 
6 0 8 5 . 8 
MEASUREMENTS OF M52B TUMOURS IN NUDE BALB/c MICE CONSUMING EPO, 
SSO OR HCO SUPPLEMENTED CHOW; OR NORMAL CHOW 
Experiment 1 
No. o f 
d a y s ( 
f o l l o v d n g 
















8 . 3 6 . 3 
1 1 . 5 7 . 2 
8 . 6 7 . 5 
1 3 . 5 1 1 . 0 
1 2 . 3 1 1 . 5 
2 8 . O 1 9 . 0 
3 2 . 5 2 1 . 0 
3 6 . 5 2 5 . 0 
3 8 . 0 2 6 . 0 
Vol 
(mm3) 
1 6 4 . 7 
5 4 0 . 0 
1 6 3 0 . 1 
5 0 5 4 . 0 
7 1 6 6 . 3 
1 1 4 0 6 . 3 
12844 .O 




1 0 . 0 lO.O 
1 2 . 7 1 1 . 5 
16.O 1 6 . 0 
5 . 6 4 . 1 
1 9 . 5 1 8 . 5 
6 . 0 5 . 7 
24.O 19 .O 
9 . 0 9 . 0 
2 4 . 0 2 1 . 0 
1 2 . 0 1 1 . 0 
25 .O 1 3 . 0 




8 3 9 . 8 
2 0 9 5 . 1 
3 4 3 4 . 4 
4 6 9 6 . 5 
6018 .O 
3 0 4 8 . 5 




4 .5 4 .5 
6 . 6 6 . 6 
8 . 0 8 . 0 
9 . 5 9 . 5 
1 1 . 5 1 1 . 5 
1 3 . 0 1 3 . 0 
14.O 14 .O 
V o l . 
(mm3) 
4 5 . 6 
1 4 3 . 7 
2 5 6 . 0 
4 2 8 . 7 
7 6 0 . 4 
1 0 9 8 . 5 
1372.O 




1 5 . 5 6 . 5 
14.O 8 . 0 
16.4 8 .0 
14.8 9 . 0 
33.7 14.4 
3 9 . 5 2 7 . 8 
4 2 . 2 2 1 . 5 
4 6 . 5 2 3 . 7 
4 8 . 0 2 4 . 0 
V o l . 
(mm3) 
7 7 5 . 4 
1 1 2 4 . 2 
3 4 9 4 . 0 
1 5 2 6 3 . 6 
9 7 5 3 . 5 
1 3 0 5 9 . 3 
13824 .O 




1 4 . 5 1 1 . 5 
2 0 . 4 1 5 . 1 
2 5 . 7 2 0 . 0 
2 9 . 0 2 3 . 0 
3 0 . 3 2 1 . 5 
3 2 . 0 2 5 . 0 
3 4 . 0 2 6 . 0 
V o l . 
(nm3) 
9 5 8 . 8 
2 3 2 5 . 7 
5 1 4 0 . 0 
7 6 7 0 . 5 
7 0 0 3 . 1 
1000O.O 
1 1 4 9 2 . 0 
9 . 5 0 
Mean v o l . 
(mm3) 
n=5 
4 8 8 . 9 
9 9 4 . 7 
2 5 2 3 . 0 
6 3 7 0 . 2 
5 8 7 6 . 0 
8 3 1 6 . 4 
8 5 1 6 . 1 
SEM 
1 7 3 . 9 
3 7 0 . 4 
8 3 4 . 0 
2 5 1 4 . 3 
1 5 0 8 . 8 
2 1 4 7 . 8 
2 6 1 4 . 3 
MEASUREMENTS OF M52B TUMOURS IN NUDE BALB/c MICE CONSUMING 
EPO, SSO OR HCO SUPPLEMENTED CHOW; OR NORMAL CHOW 
Experiment 1 
No. o f 
d a y s 
f o l l o w i n g 










( g ) 
L 
1 1 . 0 
6 . 0 
1 5 . 0 
2 3 . 5 
2 7 . 5 
3 4 . 0 
4 0 . 0 




1 1 . 0 
6 . 0 
8 . 8 
2 0 . 0 
2 1 . 5 
2 9 . 5 
3 3 . 0 
3 3 . 0 
1 1 . 8 0 
V o l 5 
(mm ) 
7 7 3 . 5 
5 8 0 . 8 
4 7 0 0 . 0 
6 3 5 5 . 9 
1 4 7 9 4 . 3 
2 1 7 8 0 . 0 





5 . 5 
5 . 5 
7 . 7 
9 . 5 
4 . 8 
2 1 . 0 
1 1 . 2 
2 3 . 5 
1 2 . 0 
3 2 . 5 
1 2 . 5 
3 9 . 0 
4 0 . 0 
9 . 
4 . 6 
5 . 5 
7 . 5 
8 . 8 
4 . 8 
1 1 . 8 
1 0 . 0 
1 5 . 3 
9 . 5 
1 6 . 5 
1 0 . 0 
2 9 . 0 




V o l , 
(mm ) 
1 4 1 . 4 
6 3 9 . 7 
2 0 2 2 . 0 
3 2 9 2 . 1 
5 0 4 9 . 1 





9 . 2 6 . 5 
11.O lO.O 
9 . 5 8 . 5 
1 8 . 0 17.O 
1 3 . 5 1 3 . 0 
3 2 . 7 1 6 . 8 
4 7 . 0 28 .O 
4 0 . 0 3 6 . 5 
4 3 . 0 3 9 . 0 
4 4 . 0 4 0 . 0 
l l . H O 
V o l . 
(mm3) 
1 0 8 7 . 5 
3 6 9 9 . 5 
4 6 1 4 . 6 
1 8 4 2 4 . 0 
2 6 6 4 5 . 0 
3 2 7 0 1 . 5 
3 5 2 0 0 . 0 
L 
( 
8 . 0 
~ 8 . 0 
4 . 7 
8 . 5 
1 9 . 0 
3 4 . 8 
4 0 . 7 
4 7 . 0 
4 8 . 5 




8 . 0 
6 . 0 
4 . 7 
8 . 5 
9 . 0 
1 6 . 5 
1 7 . 3 
2 1 . 3 
2 3 . 5 
2 4 . 0 
1 4 . 2 0 
Vol . 
(mm3) 
4 5 1 . 9 
1 0 7 6 . 6 
4 7 3 7 . 2 
6 0 9 0 . 6 
1 0 6 6 1 . 7 
1 3 3 9 2 . 1 





5 . 0 
6 . 0 
1 0 . 0 
1 0 . 7 
1 4 . 5 
7 . 0 
1 5 . 7 
6 . 0 
2 1 . 0 
2 3 . 0 
4 . 0 
6 . 0 
8 . 5 
1 0 . 0 
1 2 . 5 
5 . 5 
1 4 . 0 
6 . 0 
17 .O 
1 8 . 0 
1 . 6 4 
• 
V o l . 
(mm3) 
4 0 . 0 
1 0 8 . 0 
3 6 1 . 2 
5 3 5 . 0 
1238 .7 
1 6 4 6 . 6 
6 7 6 0 . 5 
Mean v o l . 
(mm3) 
n=5 
4 9 8 . 9 
1 2 2 0 . 9 
3287 .O 
6 9 3 9 . 5 
1 1 6 7 7 . 8 
1 7 1 8 3 . 9 
1 9 2 7 9 . 4 
SEM 
1 9 5 . 3 
6 3 8 . 4 
8 9 5 . 1 
306O.0 
4 4 0 2 . 7 
5 0 9 0 . 8 
4 7 3 1 . 8 
MEASUREMENTS OF M52B TUMOURS IN NUDE BALB/c MICE CONSUMING 
EPO, SSO OR HCO SUPPLEMENTED CHOW: OR NORMAL CHOW 
Experiment 1 
No. o f 
d a y s 
f o l l o v d n g 










( g ) 
L 
8 . 0 
6 . 5 
1 2 . 0 
1 5 . 0 
1 6 . 8 
1 7 . 5 
1 9 . 8 
2 1 . 5 
2 3 . 7 
2 3 . 5 
2 7 . 0 




6 . 0 
6 . 5 
1 0 . 0 
1 3 . 0 
1 3 . 0 
1 7 . 0 
1 4 . 3 
1 9 . 0 
2 2 . 0 
2 1 . 0 
2 4 . 0 
3 1 . 0 
Vol . 
(mm3) 
1 4 4 . 0 
7 3 7 . 3 
2 6 8 7 . 1 
4 5 5 3 . 2 
9 6 1 6 . 2 
1 2 9 5 7 . 8 
2 2 5 8 3 . 5 





8 . 0 
1 0 . 0 
1 0 . 5 
1 2 . 0 
1 7 . 6 
3 1 . 5 
3 6 . 0 
3 7 . 0 
6 . 5 
9 . 0 
8 . 3 
1 2 . 0 
1 7 . 3 
2 1 . 5 
2 6 . 0 
2 7 . 0 
V o l , 
(mm ) 
1 6 9 . 0 
4 0 5 . 0 
1225 .7 
2 6 3 3 . 8 
7 2 8 0 . 4 
12168.O 
1 3 4 8 6 . 5 




8 . 5 
1 1 . 0 
1 2 . 0 
1 2 . 5 
1 8 . 2 
1 4 . 7 
2 0 . 6 
1 5 . 5 
2 2 . 8 
3 0 . 0 
1 6 . 5 
2 4 . 0 
2 4 . 0 





8 . 5 
1 0 . 8 
8 . 5 . 
1 2 . 5 
1 2 . 0 
1 3 . 2 
1 3 . 5 
1 3 . 2 
1 4 . 1 
7 . 7 
1 4 . 5 
1 6 . 0 
1 6 . 0 
16 .O 
(n=5) 
V o l . 
(mm3) 
3 0 7 . 1 
1 0 7 5 . 0 
2 2 8 7 . 0 
3 1 5 7 . 8 
4 5 0 6 . 1 
4 8 0 6 . 6 
5 2 4 8 . 0 
4 . 1 8 
L 
7 . 3 
1 2 . 0 
9 . 5 
2 7 . 0 
3 0 . 7 
3 3 . 8 
3 6 . 0 




7 . 3 
lo.o 
9 . 5 
1 7 . 0 
1 8 . 3 
2 3 . 0 
2 5 . 0 
3 0 . 0 
V o l . 
(mm3) 
1 9 4 . 5 
1 0 2 8 . 7 
3 9 0 1 . 5 
5 1 4 0 . 6 
8 9 4 0 . 1 
1 1 2 5 0 . 0 
1 8 9 0 0 . 0 
9 . 2 0 
L 
( 
1 0 . 0 
4 . 5 
6 . 5 
lo.o 
1 4 . 5 
6 . 5 
1 9 . 5 
2 9 . 0 




5 . 0 
4 . 5 
5 . 8 
1 0 . 0 
1 3 . 0 
6 . 5 
1 8 . 8 
2 3 . 5 
2 8 . 0 
6 . 5 0 
V o l . 
(mm3) 
1 2 5 . 0 
1 5 4 . 9 
5 0 0 . 0 
1 3 6 2 . 6 
3 4 4 6 . 0 
8 0 0 7 . 6 
1 2 9 3 6 . 0 
Mean v o l . 
(mm3) 
n=5 
1 8 7 . 9 
6 8 0 . 2 
2 1 2 0 . 3 
3 3 6 9 . 6 
6 7 5 7 . 8 
9 8 3 8 . 0 
1 4 6 3 0 . 8 
SEM 
3 2 . 0 
1 7 7 . 8 
5 8 9 . 4 
6 7 6 . 5 
1 2 0 9 . 2 
1 5 1 3 . 6 
2 9 4 7 . 0 
APPENDIX 5.2 
MEASUREMENTS OF M52B TUMOURS IN NUDE BALB/c MICE 
CONSUMING EITHER NORMAL OR EPO SUPPLEMENTED CHOW 
Experiment 2 
No. o f 
days 
f o l l o v d n g 







( g ) 
L 
1 4 . 7 
2 4 . 0 
2 5 . 5 




1 4 . 7 
1 9 . 0 
1 9 . 5 
2 1 . 0 
4 . 0 0 
I n v a s 
tumou 
V o l . 
(mm ) 
1 5 8 8 . 3 
4 3 3 2 . 0 
4 8 4 8 . 2 
7 7 1 5 . 5 





2 2 . 0 1 7 . 3 
3 1 . 0 2O.0 
3 9 . 5 3 5 . 0 
3 8 . 0 3 6 . 5 
8 . 5 0 
I n v a s i 
tumour 
Tumour measurements 
Contro l (n=8) 
V o l . 
(ran ) 
3 2 9 2 . 2 
6200 .O 
2 4 1 9 3 . 8 





8 . 6 8 . 6 
5 . 0 5 . 0 
15.O 14.O 
9 . 0 6 . 8 
7 . 0 6 . 0 
2 7 . 0 1 9 . 5 
1 1 . 2 9 . 0 
3 9 . 4 2 2 . 0 
V o l . 
(mm3) 
3 8 0 . 5 
1 8 0 4 . 1 
5587 .O 
9 5 3 4 . 8 
4 . 0 0 
I n v a s i v * 
tumour 
L 
1 1 . 5 
3 8 . 0 
1 7 . 0 
3 3 . 0 




1 0 . 5 
1 6 . 0 
8 . 5 
2 3 . 7 
2 7 . 0 
6 . 4 4 
I n v a s i v e 
tumour 
V o l . 
(mm3) 
6 3 3 . 9 
5 4 7 8 . 1 
9 2 6 7 . 9 
1 3 5 5 9 . 4 
L 
(mm) 
7 . 7 
8 . 2 
1 2 . 2 
9 . 8 
2 5 . 3 
2 7 . 5 
5 
e 
7 . 0 
7 . 2 
9 . 7 
9 . 5 
1 5 . 5 
1 7 . 5 
V o l . 
(mm3) 
4 0 1 . 2 
1 0 1 6 . 2 
3 0 3 6 . 2 
4 2 1 0 . 9 
8 . 2 0 















































































2 .0 1.0 
4 . 0 3.5 
7 .5 5.7 
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1 0 . 0 
9 . 5 
3 9 . 0 
1 4 . 5 
4 2 . 5 
1 7 . 5 
4 8 . 5 




8 . 0 
7 . 0 
7 . 5 
1 3 . 0 
1 0 . 5 
1 7 . 5 
1 1 . 5 
2 0 . 5 
1 2 . 0 
V o l . 
(mm3) 
8 3 2 . 2 
4 0 9 4 . 8 
7 6 6 5 . 0 
1 1 6 5 9 . 9 
5 . 8 0 




9 . 5 
1 8 . 0 
1 5 . 0 
3 9 . 0 






8 . 0 
1 0 . 5 
1 2 . 0 
2 2 . 0 
2 4 . 5 
V o l . 
(mm3) 
3 0 4 . 0 
2 0 7 2 . 3 
9438 .O 
1 3 5 0 5 . 6 
7 . 0 0 





1 6 . 5 lO.O 
1 9 . 5 1 1 . 0 
2 2 . 0 1 4 . 0 
2 2 . 0 1 6 . 5 
2 9 . 5 2 0 . 5 
2 8 . 5 1 8 . 5 
4 4 . 0 3 7 . 0 
4 . 3 0 
I n v a s i v e 
Tumour 
V o l . 
(mm3) 
2 0 0 4 . 8 
5 1 5 0 . 8 
1 1 0 7 5 . 8 
3O118.0 
L 
1 8 . 0 
3 6 . 0 
3 9 . 0 
4 0 . 0 




1 3 . 0 
1 4 . 0 
2 6 . 0 
3 0 . 0 




1 3 1 8 2 . 0 
1 8 0 0 0 . 0 
27562 .5 
1 4 . 2 0 




7 . 0 
1 0 . 0 
1 6 . 0 
4 . 5 
1 3 . 2 
2 0 . 5 
6 . 0 
1 6 . 0 
2 5 . 0 
1 1 . 0 
5 
e 
5 . 0 
9 . 5 
7 . 0 
4 . 0 
1 3 . 0 
1 1 . 5 
5 . 0 
1 3 . 0 
1 8 . 5 
7 . 5 
Vol^ 
(mm ) 
8 7 . 5 
8 7 9 . 3 
2546 .O 
5 9 3 9 . 5 
2 . 0 0 
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f o l l o w i n g 











6 . 0 6 . 0 
1 2 . 0 8 . 5 
1 3 . 5 9 . 0 
2 9 . 0 2 1 . 5 
3 5 . 0 2 6 . 0 
4 . 5 4 
i n v a s i v e 
tumour 
V o l . 
(mm3) 
1 0 8 . 0 
9 8 0 . 3 





1 3 . 5 7 . 0 
2 2 . 5 9 . 7 
2 9 . 7 1 1 . 5 
3 3 . 5 1 5 . 0 
2 . 2 8 
non 
i n v a s i v 
tumour 
V o l . 
(mm3) 
3 3 0 . 8 
1 0 5 8 . 5 
1 9 6 3 . 9 
3 7 6 8 . 8 
> 
Tumour measurements 




2 . 0 1 . 0 
1 2 . 4 1 0 . 5 
1 8 . 0 1 4 . 9 
2 4 . 5 1 8 . 5 
V o l . 
(mm3) 
l . O 
6 8 3 . 6 
1 9 9 8 . 1 
4 1 9 2 . 6 
2 . 0 0 
non 





1 2 . 0 4 . 5 
2 0 . 0 1 0 . 5 
2 5 . 0 1 1 . 0 
3 3 . 0 1 7 . 5 
2 . 3 0 
i n v a s i v e 
tumour 
V o l . 
(irai3) 
1 2 1 . 5 
1 1 0 2 . 5 
1 5 1 2 . 5 
5 0 5 3 . 1 2 
L 
( 
1 1 . 4 
1 4 . 5 
7 . 4 
2 3 . 4 




5 . 5 
9 . 0 
4 . 7 
1 7 . 5 
1 9 . 0 
3 . 1 0 
V o l . 
(mm3) 
1 7 2 . 4 
6 6 9 . 0 
3 5 8 3 . 1 
5 1 4 4 . 3 




1 . 0 
7 . 5 
5 .7 
lo.o 
1 1 . 0 
3 1 . 0 
6 
e 
1 . 0 
6 . 5 
5 .7 
6 . 8 
6 . 8 
1 4 . 5 
V o l . 
(ran3) 
0 . 5 
2 5 1 . 0 
4 8 5 . 5 
3 2 5 8 . 9 
0 . 4 1 
non 
i n v a s i v e 
tumour 
Mean v o l . 
(mm3) 
n=6 
1 2 2 . 4 
7 9 0 . 8 
2 7 0 7 . 5 
5 5 4 1 . 3 
SEM 
5 0 . 2 
1 3 2 . 0 
8 9 7 . 2 
1 2 9 2 . 5 
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Mean v o l . 
(mm ) 
n=6 







4 6 9 . 3 
1145.4 
APPENDIX 6 .1 
MEASUREMENTS OF NUB 1 TUMOURS IN NUDE BALB/c MICE 











































































MEASUREMENTS OF NUB 1 TUMOURS IN NUDE B A L B / c MICE 
CONSUMING EITHER NORMAL OR EPO SUPPLEMENTED DIETS 
Experiment 1 
No. o f 
d a y s 
f o l l o w i n g 











3 . 5 
3 . 5 
3 . 5 
8 . 0 
8 . 0 
1 0 . 4 




2 . 0 
2 . 0 
2 . 0 
4 . 5 
5 . 9 
6 . 0 
5 . 0 
0 . 0 
V o l . 
(mm3) 
7 . 0 
7 . 0 
7 . 0 
8 1 . 0 
1 3 9 . 2 






6 . 5 4 . 8 
6 . 5 5 . 0 
8 . 0 6 . 0 
9 . 0 8 . 0 
1 0 . 5 7 . 9 




V o l . 
(mm3) 
7 4 . 9 
8 1 . 3 
1 4 4 . 0 
2 8 8 . 0 
3 2 7 . 7 




1 .5 1 .5 
3 . 0 3 . 0 
3 . 0 3 . 0 
4 . 0 3 . 0 
5 . 5 3 . 5 
5 . 0 4 . 5 
O.Ol 
V o l . 
(ran ) 
1 .7 
1 3 . 5 
1 3 . 5 
1 8 . 0 
3 3 . 6 
5 0 . 6 
L 
(mm) 
2 . 5 
2 . 0 
3 . 0 
2 . 0 
3 . 5 
2 . 0 
5 . 0 
2 . 0 
5 . 7 
2 . 3 
6 . 3 
2 . 3 
4 
e 
2 . 5 
2 . 0 
3 . 0 
2 . 0 
3 . 5 
2 . 0 
5 . 0 
2 . 0 
5 . 0 
2 . 3 
5 . 1 
2 . 3 
V o l 5 
(mm ) 
1 1 . 8 
1 7 . 5 
2 5 . 4 
6 6 . 5 
7 7 . 3 
8 8 . 0 
0 . 0 1 
APPENDIX 6.2 
MEASUREMENTS OF NUB 1 XENOGRAFTS IN NUDE BALB/c MICE 
CONSUMING EITHER NORMAL CHOW OR EPO SUPPLEMENTED CHOW 
Experiment 2 
No o f 
tteys 
f o l l o w i n g 










6 . 5 5 . 0 
8 . 2 6 . 4 
8 . 2 7 . 0 
1 2 . 1 9 . 5 
1 2 . 5 1 1 . 5 
1 4 . 0 13 .O 
V o l . 
(mm3) 
8 1 . 3 
1 6 7 . 9 
2 0 0 . 9 
5 4 6 . 0 
8 2 5 . 6 





4 . 0 
4 . 8 
6 . 2 
7 . 2 
8 . 8 
3 . 0 
lO.O 
4 . 5 
3 . 0 
3 . 6 
5 . 5 
5 . 8 
6 . 5 
3 . 0 
8 . 0 
4 . 5 
V o l . 
(mm3) 
1 8 . 0 
3 1 . 1 
9 3 . 8 
1 2 1 . 1 
1 9 9 . 4 
3 6 5 . 6 
Tumour measurements 




6 . 4 3 . 0 
6 . 6 3 . 5 
6 . 4 3 . 6 
7 . 8 3 . 7 
6 . 5 3 . 5 
8 . 5 4 . 0 
V o l . 
(ran3) 
2 8 . 8 
4 0 . 4 
4 1 . 5 
5 3 . 3 
3 9 . 8 




3 . 2 3 . 2 
6 . 6 4 . 1 
7 . 1 4 . 6 
8 . 5 6 . 3 
9 . 0 6 . 0 
9 . 0 6 . 5 
V o l . 
(mm3) 
1 6 . 3 
5 5 . 5 
7 5 . 1 
1 6 8 . 7 
1 6 2 . 0 
1 9 0 . 1 
L 
3 . 0 
3 . 0 
2 . 5 
4 . 6 
4 . 1 
4 . 6 
5 . 6 
4 . 1 
5 . 2 
9 . 0 
6 . 9 
8 . 9 
8 . 4 




3 . 0 
3 . 0 
2 . 5 
4 . 4 
2 . 7 
4 . 3 
4 . 8 
3 . 1 
4 . 6 
6 . 0 
6 . 8 
6 . 0 
8 . 4 
7 . 0 
9 . 2 
5 
V o l . 
(mm3) 
3 4 . 8 
1 0 2 . 0 
1 3 9 . 2 
3 2 1 . 5 
4 5 6 . 6 
7 1 7 . 2 
L 
( 
3 . 0 
3 . 8 
4 . 3 
5 . 5 
8 . 3 




3 . 0 
3 . 8 
4 . 3 
5 . 4 
6 . 5 
6 . 6 
V o l . 
(ran3) 
1 3 . 5 
2 7 . 4 
3 9 . 8 
8 0 . 2 
1 7 5 . 3 
2 2 8 . 7 
Mean v o l . 
(ran3) 
n=6 
3 2 . 1 
7 0 . 7 
9 8 . 4 
2 1 5 . 2 
3 0 9 . 9 
4 5 8 . 8 
SEM 
1 0 . 4 
2 2 . 5 
2 5 . 5 
7 6 . 9 
1 1 7 . 9 
1 7 1 . 7 
Experiment 2 (Control cont.) 
No. o f 
d a y s 
f o l l o w i n g 












15 .O 1 5 . 0 
17 .O 1 5 . 5 
17 .O 1 6 . 0 
2 1 . 0 1 7 . 0 
2 1 . 5 1S.O 
V o l . 
(mm3) 
1 6 8 7 . 5 
2 0 4 2 . 1 
2 1 7 6 . 1 
3 0 3 4 . 5 
3 4 8 3 . 0 




1 1 . 5 lO.O 
1 2 . 5 1 1 . 5 
1 4 . 5 1 2 . 5 
1 6 . 5 1 6 . 0 
1 7 . 7 1 7 . 0 
1 . 5 6 
V o l . 
(mm3) 
5 7 5 . 0 
8 2 6 . 6 
1 1 3 2 . 8 
2 1 1 2 . 0 





5 . 5 4 . 3 
7 . 0 4 . 0 
8 . 5 5 . 0 
8 . 0 5 . 0 
6 . 4 4 . 3 
0 . 1 5 
C o n t r o l (n=6) 
V o l . 
(mm3) 
5 0 . 8 
5 6 . 0 
1 0 6 . 3 
1 0 0 . 0 




1 0 . 5 7 . 0 
4 . 0 4 . 0 
9 . 5 7 . 0 
4 . 7 4 . 7 
1 1 . 0 7 . 5 
4 . 5 4 . 5 
1 2 . 0 8 . 5 
7 . 0 6 . 5 
1 2 . 5 8 . 2 
7 . 2 6 . 1 
4 . 5 4 . 5 
0 . 4 6 
V o l . 
(mm3) 
2 8 9 . 2 
2 8 4 . 7 
3 5 4 . 9 
5 8 1 . 3 




1 3 . 0 6 . 2 
1 1 . 3 1 0 . 0 
V o l . 
(mm3) 
8 1 4 . 9 
S a c r i f i c e d 




1 2 . 0 8 . 5 
1 2 . 0 9 . 0 
1 4 . 0 1 2 . 0 
1 6 . 5 1 2 . 0 
1 6 . 0 1 2 . 0 
V o l . 
(mm3) 
4 3 3 . 5 
4 8 6 . 0 
1 0 0 8 . 0 
1 1 8 8 . 0 
1 1 5 2 . 0 
0 . 3 0 
Mean v o l . 
(mmO 
n=6 
6 4 1 . 9 
7 3 9 . 1 
9 5 5 . 5 
1 4 0 3 . 2 
1 5 7 0 . 3 
SEM 
2 3 5 . 1 
3 5 0 . 4 
3 6 1 . 9 
5 2 9 . 8 
6 3 5 . 5 
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1 5 . 5 6 . 5 
2 0 . 9 9 . 2 
24.O lO.O 
2 9 . 3 1 2 . 8 
3 0 . 5 1 3 . 5 
3 2 . 0 1 5 . 0 
V o l . 
(mm3) 
3 2 7 . 4 
8 8 4 . 5 
1 2 0 0 . 0 
2 4 0 0 . 3 
2 7 7 9 . 3 




7 . 0 4 . 1 
1 1 . 3 6 . 0 
1 2 . 4 lO.O 
1 3 . 5 1 0 . 4 
1 5 . 5 1 2 . 5 
1 5 . 5 15 .O 
V o l . 
(mm3) 
5 8 . 8 
2 0 3 . 4 
6 2 0 . 0 
7 3 0 . 1 
1 2 1 0 . 9 






5 . 5 
6 . 5 
5 . 5 
6 . 8 
7 . 8 
6 . 6 
8 . 2 
1 0 . 5 
8 . 5 
9 . 5 
1 1 . 5 
1 1 . 0 
2 3 . 3 
lO.O 
2 7 . 0 
l l . O 
4 . 0 
4 . 0 
5 . 5 
5 . 5 
5 . 3 
6 . 1 
7 . 6 
7 . 0 
7 . 6 
9 . 0 
7.C 
8 . 7 
1 0 . 5 
9 . 7 
1 1 . 5 
1 1 . 0 
EPO (n=6) 
V o l . 
(mm3) 
1 7 9 . 2 
3 3 5 . 2 
7 3 9 . 5 
1 0 8 2 . 8 
1 7 5 4 . 9 




6 . 6 5 . 5 
4 . 5 4 . 5 
8 . 3 7 . 3 
6 . 3 6 . 3 
1 2 . 1 9 . 6 
7 . 8 7 . 8 
1 3 . 5 1 1 . 5 
8 . 7 8 . 7 
2 3 . 4 1 3 . 3 
2 4 . 5 1 2 . 5 
V o l . 
(mm3) 
1 4 5 . 4 
3 4 6 . 2 
7 9 4 . 8 
1 2 2 1 . 9 
2 0 6 9 . 6 




1 1 . 9 
1 3 . 5 
1 6 . 4 
1 8 . 5 




3 . 9 
5 .7 
7 . 0 
8 . 1 
9 . 0 
1 0 . 5 
V o l . 
(mm3) 
7 6 . 1 
1 9 3 . 3 
3 3 0 . 8 
5 3 8 . 0 
7 4 9 . 3 





5 . 0 
7 . 3 
9 . 8 
8 . 5 
1 1 . 5 
1 2 . 0 
4 . 2 
5 . 8 
6 . 2 
6 . 3 
8 . 0 
8 . 0 
V o l . 
(mm3) 
4 4 . 1 
1 2 2 . 7 
1 8 8 . 3 
1 6 8 . 7 
3 6 8 . 0 
3 8 4 . O 
Mean v o l . 
(mm3 ) 
n=6 
1 3 8 . 5 
3 4 7 . 4 
6 4 5 . 6 
1 0 2 3 . 6 
1 4 8 8 . 7 
1 8 6 5 . 9 
SEM 
4 7 . 4 
1 2 3 . 6 
1 6 0 . 6 
3 4 5 . 3 
3 9 7 . 0 
4 9 4 . 9 
(cont . ) : 
Experiment 2 
No. o f 
d a y s 
f o l l o w i n g 












3 3 . 5 1 5 . 5 
S a c r i f i c e d 
V o l f 
(mm ) 
4 0 2 4 . 2 




1 7 . 0 1 5 . 0 
2 1 . 8 1 3 . 5 
2 3 . 5 1 3 . 7 
2 7 . 5 1 6 . 5 
3 0 . 5 1 5 . 5 
Vol f 
(mm ) 
1 9 1 2 . 5 
1 9 8 6 . 5 
2 2 0 5 . 3 
3 7 4 3 . 4 
3 6 6 3 . 8 







2 9 . 0 
1 3 . 0 
3 1 . 8 
1 3 . 9 
3 0 . 0 
1 4 . 5 
1 5 . 0 
3 0 . 5 
1 5 . 5 
3 7 . 0 
1 3 . 0 
1 3 . 0 
1 4 . 2 
1 2 . 0 
1 6 . 0 
1 2 . 0 
1 3 . 2 
1 8 . 0 
1 2 . 5 
1 9 . 0 
V o l j 
(mm ) 
3 5 4 9 . 0 
4 2 0 6 . 9 
4 8 8 4 . 0 
6 2 4 7 . 8 
7 8 8 9 . 4 




2 7 . 5 1 4 . 0 
2 6 . 0 1 4 . 0 
2 6 . 5 1 5 . 0 
2 8 . 5 1 4 . 5 
2 7 . 5 1 3 . 5 
0 . 3 4 
V o l . 
(mm3) 
2 6 9 5 . 0 
2 5 4 8 . 0 
2 9 8 1 . 3 
2 9 9 6 . 1 
2 5 0 5 . 9 
L 
( 
2 2 . 5 
2 5 . 0 
2 5 . 5 
2 6 . 5 




1 1 . 5 
1 3 . 5 
1 4 . 0 
1 5 . 5 
1 8 . 0 
2 . 
V o l . 
(mm3) 
1 4 8 7 . 1 
2 2 7 8 . 1 
2 4 9 9 . 0 
3 1 8 3 . 3 






l l . O 
1 0 . 8 
1 2 . 0 
1 2 . 5 
5 . 8 
1 4 . 0 
5 . 5 
8 . 5 
9 . 3 
9 . 0 
8 . 7 
5 . 8 
8 . 2 
5 . 5 
3 . 5 0 
V o l . 
(mm3) 
3 9 7 . 3 
4 6 7 . 0 
4 8 6 . 0 
5 7 0 . 6 
5 5 3 . 9 
Mean v o l . 
(nrn3) 
n=6 
2 3 4 4 . 2 
2 2 9 7 . 3 
2 6 1 1 . 1 
3 3 4 8 . 2 
3 8 4 6 . 0 
SEM 
6 0 2 . 5 
5 9 9 . 8 
7 0 8 . 9 
9 0 8 . 8 
1 2 2 0 . 1 
PERCENT INCREASE IN VOLUME OF NUB 1 XENOGRAFTS IN NUDE BALB/c MICE 
CONSUMING EITHER NORMAL CHOW OR EPO SUPPLEMENTED CHOW 
Experiment 2 
No. o f 
d a y s 
f o l l o w i n g 









0 . 0 
1 0 6 . 6 
1 4 7 . 3 
5 7 2 . 0 
9 1 6 . 1 
1 3 5 6 . 0 
1 9 7 6 . 9 
2 
O.O 
7 2 . 8 
4 2 0 . 9 
5 7 2 . 7 
1 0 0 7 . 8 
1 9 3 0 . 9 
3 0 9 4 . 4 
Contro l (n=6) 
P e r c e n t i n c r e a s e i n tumour volume 
3 4 
0 . 0 O.O 
4 0 . 3 2 4 0 . 3 
4 4 . 0 3 6 0 . 8 
8 5 . 4 9 3 4 . 8 
3 8 . 2 8 9 3 . 9 
1 3 6 . 1 1 0 6 6 . 4 
7 6 . 5 1 6 4 7 . 5 
r e l a t i v e t o day 0 
5 
O.O 
1 9 3 . 0 
3 0 0 . 0 
8 2 3 . 9 
1 2 1 1 . 9 
1 9 6 0 . 9 
2 2 4 1 . 6 
6 
O.O 
1 . 0 
1 9 4 . 4 
4 9 4 . 0 
1 1 9 8 . 7 
1 5 9 4 . 0 
3 1 1 1 . 1 
Mean 
O.O 
1 0 9 . 0 
2 4 4 . 7 
5 8 0 . 5 
8 7 7 . 8 
1 3 4 0 . 7 
2 0 2 9 . 2 
SEM 
-
3 7 . 4 
5 7 . 7 
1 2 0 . 8 
1 7 6 . 8 
2 7 8 . 3 
4 5 8 . 0 
PERCENT INCREASE IN VOLUME OF NUB 1 XENOGRAFTS IN NUDE BALB/c MICE 








































tumour volume r e l a t i v e to day 0 
4 5 















Mean v o l . 















APPENDIX 6 . 3 
MEASUREMENTS OF NUB 1 TUMOURS IN NUDE BALB/c MICE 
CONSUMING EITHER NORMAL OR EPO SUPPLEMENTED DIETS 
Experiment 3 
No. o f 
days 
f o l l o w i n g 















9 . 0 
8 . 2 
9 . 8 
8 . 5 
9 . 2 
1 
e 
4 . 3 
5 . 3 
5 . 0 
4 . 7 
4 . 7 
4 . 0 
4 . 0 
V o l . 
(mm3) 
9 2 . 5 
1 4 0 . 5 
1 1 2 . 5 
9 0 . 6 
1 0 8 . 2 
6 8 . 0 
7 3 . 6 




6 . 0 4 . 9 
9 . 0 5 . 8 
1 0 . 5 7 . 2 
1 2 . 7 1 1 . 0 
1 4 . 0 1 0 . 9 
1 6 . 4 1 2 . 5 
1 8 . 4 1 5 . 6 
O.T9 
V o l . 
(mm3) 
7 2 . 0 
1 5 1 . 4 
2 7 2 . 2 
7 6 8 . 4 
8 3 1 . 7 
1 2 8 1 . 3 
2 2 3 8 . 9 
Tumour measurements 




3 . 7 3 . 5 
4 . 9 4 . 9 
4 . 6 4 . 6 
4 . 8 4 . 2 
5 . 8 4 . 5 
6 . 2 5 . 0 
6 .7 5.5 
4 . 8 4 . 8 
1 2 . 8 7 . 0 
5 . 3 5 . 0 
1 4 . 0 6 . 4 
1 7 . 0 7 . 0 
1 8 . 1 8 . 7 
0 . 4 
V o l . 
(mm3) 
1 3 0 . 1 
1 0 1 . 0 
2 3 4 . 1 
3 7 9 . 9 
2 8 6 . 7 
4 1 6 . 5 
6 8 5 . 0 
19 
L 
4 . 3 
6 . 3 
1 1 . 0 
1 2 . 8 
1 7 . 7 
1 8 . 5 
2 0 . 0 




3 . 8 
5 . 8 
4 . 5 
4 . 5 
6 . 7 
7 . 3 
8 . 2 
lO.O 
V o l . 
(mm ) 
1 3 7 . 0 
1 1 1 . 4 
1 2 9 . 6 
3 9 7 . 2 
4 9 2 . 9 
6 7 2 . 4 
1 0 2 5 . 0 
0 . 4 7 
L 
( 
4 . 9 
7 . 0 
7 . 2 
7 . 5 
7 . 3 
7 . 3 
7 . 3 
e 
inn) 
4 . 9 
5 . 3 
6 . 5 
7 . 0 
6 . 5 
6 . 5 
6 . 6 
S 
v o l . 
(mm3) 
5 8 . 8 
9 8 . 3 
1 5 2 . 1 
1 8 3 . 8 
1 5 4 . 2 
1 5 4 . 2 
1 5 9 . 0 




7 . 2 4 . 0 
7 . 5 4 . 0 
7 . 4 4 . 0 
6 . 0 4 . 5 
6 . 5 4 . 5 
4 . 5 4 . 2 
4 . 5 4 . 2 
O.0O1 
V o l . 
(mm3) 
5 7 . 6 
6 0 . 0 
5 9 . 2 
6 0 . 7 
6 5 . 8 
3 9 . 7 
3 9 . 7 
NO. Of 
d a y s 
f o l l o w i n g 










( g ) 
L 
7 . 5 
7 . 6 
9 . 7 
1 1 . 3 
1 3 . 3 
1 5 . 1 




4 . 6 
5 . 2 
5 . 9 
7 . 0 
7 . 0 
7 . 5 
8 . 5 
< 
V o l . 
(mm3) 
7 9 . 4 
1 0 2 . 8 
1 6 8 . 8 
2 7 6 . 9 
3 2 5 . 9 
4 2 4 . 7 






6 . 9 
9 . 2 
1 0 . 8 
1 0 . 4 
1 0 . 8 
1 2 . 7 
1 3 . 2 
4 . 3 
4 . 5 
5 . 0 
5 . 8 
6 . 3 
6 . 5 




V o l . 
(ran3) 
6 3 . 8 
9 3 . 2 
1 3 5 . 0 
1 7 4 . 9 
2 1 4 . 3 
2 6 8 . 3 
2 8 7 . 5 
14 




5 . 2 3 . 5 
7 . 0 5 . 0 
1 4 . 5 6 . 8 
1 3 . 8 1 0 . 0 
1 4 . 3 8 . 4 
1 7 . 7 lO.O 
1 9 . 5 1 1 . 5 
V o l . 
(mm3) 
3 1 . 9 
8 7 . 5 
3 3 5 . 2 
6 9 0 . 0 
5 0 4 . 5 
8 8 5 . 0 
1 2 8 9 . 4 
0 . 6 5 
L 0 
(mm) 
4 . 4 
5 . 5 
6 . 3 
9 . 5 
9 . 5 
1 2 . 1 
1 4 . 7 
3 . 8 
5 . 5 
6 . 3 
9 . 5 
8 . 8 
9 . 6 
1 2 . 0 
0 . 5 0 
lo 
V o l . 
(ran3) 
3 1 . 8 
8 3 . 2 
1 2 5 . 0 
4 2 8 . 7 
3 6 7 . 8 
5 5 7 . 6 





8 . 0 
5 . 1 
8 . 5 
5 . 7 
1 2 . 5 
1 6 . 5 
1 6 . 9 
1 7 . 7 
1 9 . 0 
5 . 1 
3 . 7 
5 . 8 
5 . 7 
7 . 0 
7 . 5 
8 . 2 




1 3 8 . 9 
2 3 5 . 6 
3 0 6 . 3 
4 6 4 . 1 
5 6 8 . 2 
7 9 8 . 7 
9 5 0 . 0 




5 . 4 4 . 2 
5 . 4 4 . 5 
5 . 5 4 . 8 
6 . 2 5 . 8 
8 . 0 5 . 8 
9 . 5 6 . 2 
12 .O 7 . 0 
Vo^. 
(ran ) 
4 7 . 6 
5 4 . 7 
6 3 . 4 
1 0 4 . 3 
1 3 5 . 6 
1 8 5 . 6 





8 . 5 7 . 0 
5 . 9 4 . 0 
l l . O 6 . 9 
6 . 3 4 . 0 
1 1 . 8 7 . 8 
7 . 7 4 . 7 
2 0 . 5 8 . 8 
2 0 . 6 9 . 3 
2 4 . 8 1 0 . 8 
2 7 . 5 1 2 . 0 
1 
v o l , 
(ran ) 
2 5 5 . 4 
3 1 2 . 2 
4 4 4 . 4 
7 9 3 . 7 
8 9 0 . 8 
1 4 4 6 . 3 
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MEASUREMENTS OF NUB 1 TUMOURS IN NUDE BALB/c MICE 





















6 .0 5 .0 
7 .8 5 .2 
8.7 5 .2 
13.5 6 .5 
13.7 6 .8 
16.4 7 .6 















6.5 5 .3 
17.5 7.5 


















10.7 4 .8 
10.7 6 
11.3 6 .8 
14.8 9 .3 





1 2 3 . 3 
1 9 2 . 6 
2 6 1 . 3 
6 4 0 . 0 
7 2 6 . 5 
1 1 1 0 . 0 





2 . 7 2 . 7 
5 . 5 4 . 5 
6 . 0 5 . 5 
9 . 0 7 . 0 
10.4 7.5 
11.5 8 . 0 














4 . 3 4 .3 
3.7 3.7 
10.5 6 .5 
10.8 6.7 
14.0 8 .0 
15.4 8.8 















5.1 4 .4 
6 .3 5.5 
6.7 5.7 
9 .0 8 .0 
10.0 6.5 
12.6 7 .0 














5.7 5 .0 
7 .9 5.5 
5.5 5.5 
8 .2 7 . 0 
8.7 5.5 














EPO c o n t . : 
Experiment 3 
No. o f 
days 
f o l l o w i n g 















8 . 0 
8 . 8 
8.9 





4 . 4 
5 . 9 
6 . 0 
3 . 0 
8 . 5 
8 . 8 
lo.o 
11.7 














6 . 0 
6 . 5 
6 . 5 
6 . 5 





3 . 7 
3 . 8 
3 . 8 
3 . 8 




















8.7 7 .0 
8.5 6 .3 
8 .8 6 .5 
10.2 8 .4 


















10.0 6 .3 
11.2 7.5 
11.8 7 .3 
14.3 7.5 













7 .0 5 .0 
8.8 5 .0 
8 .4 5.7 
9.5 7 . 0 
9 .6 7 . 0 





































. 0 0 
L 





5 . 5 
4 . 7 
5 . 5 









5 . 5 
3 . 9 
4 . 5 















































6 .0 198.0 
0 .03 
EPO c o n t . : 
Experiment 3 
No. o f 
days 
fo l lowir tg 










( g ) 
L 
6 . 3 
7 . 5 
7 . 8 
1 4 . 5 
3 . 0 
1 5 . 9 
3 . 0 
1 8 . 5 




4 . 3 
5 . 3 





















4 . 5 4 . 5 
4 . 4 4 . 3 
6 . 0 5 . 0 
7 . 5 6 . 0 
8 . 6 5 . 5 
1 1 . 0 6 . 5 
1 2 . 4 8 . 0 




4 5 . 6 
4 0 . 7 
7 5 . 0 
1 3 5 . 0 
1 3 0 . 1 
2 3 2 . 4 






5 . 8 
6 . 3 
4 . 4 
6 . 0 
• 4 . 5 
6 . 5 
7 . 8 
9 . 7 
1 1 . 4 
5 . 0 
5 . 0 
4 . 4 
6 . 0 
4 . 5 
6 . 0 
5 . 8 
8 . 5 
9 . 5 
0 . 2 3 
V o l , 
(mm ) 
7 2 . 5 
1 2 1 . 3 
1 5 3 . 6 
1 1 7 . 0 
1 3 1 . 1 
3 5 0 . 4 
5 1 4 . 4 
L 9 
(mm) 
7 . 9 6 . 3 
9 . 5 6 . 0 
1 3 . 0 8 . 5 
1 7 . 5 lO.O 
1 9 . 2 1 0 . 5 
2 2 . 0 1 3 . 0 
2 2 . 8 1 3 . 0 
1 . 3 8 
19 
V o l 5 
(mm ) 
1 5 6 . 8 
1 7 1 . 0 
4 6 9 . 6 
8 7 5 . 0 
1 0 5 8 . 4 
1 8 5 9 . 0 
1 9 2 6 . 6 
Mean v o l . 
(mm ) 
n=19 
8 9 . 4 
1 4 1 . 8 
2 0 8 . 5 
4 1 6 . 8 
4 9 9 . 7 
8 3 6 . 2 
1 0 9 4 . 0 
SEM 
1 4 . 5 
2 3 . 6 
4 0 . 5 
7 2 . 8 
9 7 . 8 
185 .O 
2 2 0 . 7 
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An investigation into the effects of gamma linolenic acid 
on murine sarcoma M52B 
N.R.imchurren, J.H. Botha and W.P. l.eary 
Department of Pharmacology, University of Natal, Medical School, Box 
17039, Cnnzella -tOU. 
Addition of certain fatty acids to cultured tumour cells has been shown 
to in'Tucncc ero'.vih and morphology significantly [Abbas, Yoo and Viles 
(I9S-). Cancer Res. 42, 4639-4649; Caspar, Alanizand Brenner (1975). 
Lipids 10, 726-731]. The present study tested the effects of gamma 
iinolenic acid (Gl.A) on ihe murine sarcoma M52B. 
Initially, this sarcoma, about which little is known, was characteris-
ed. The cell line was found to be tumourigenic in newborn BAl.B/c mice. 
Histology revealed a spindle cell fibrosarcoma with a herringbone pattern. 
For in vitro studies, cells (2 x lO per flask) were cultured in Eagle's 
minimum essential medium supplemented with 10% foetal calf scrum. 
The effects of Gl.A in sodium carbonate were assessed in two ways. In 
he first experiment single doses of either 50 or 100 jig/ml Gl.A were 
id ministered. In ihe second studs' each of five flasks o{ cells were expos-
ed daily to fresh medium and 10, 20, 30, 40 or 50 /ig/ml GL.A rcspec-
ively. Control llasks for both experiments received Na.CO, only. 
All cells which received a dose of 100 pg/ml GLA had died by 4S hours, 
single exposure to 50 <ig/ml produced a similar effect after 96 hours, 
vhile at IS hours these cells had stopped dividing and had accumulated 
lense paranuclear granules. When GLA was administered daily its in-
luence on cells increased with time. These lime dependent changes ap-
>earcd to be dose related, the most pronounced effects being observed 
villi the higher concentrations of the fatty acid. Growth rates and mor-
ihologv wcie consistently unaffected by the addition of Na.CO,. 
An ('/; vivo study paralleling the //; vitro investigation is at present in 
irogress. Two groups of BAl.B/c mice with tumours of the M52B line 
ire receiving normal and GLA-supplcmenicd diets. Preliminary results 
ippcar to conflict with those of the in vitro study. 
AM 7 12), 22-2k, Aug.u*t 1985. 
SPONTANEOUS REMISSION OF M52B SARCOMAS GROWING IN 
IMMUNOCOMPETENT MICE 
N. Ramchurren and J.H. Botha, Department of Pharmacology and K.M.Robinson, 
Department of Physiology, University of Natal Medical School, P 0 Box 17039, 
- ' "" Congella 4013, Durban 
INTRODUCTION 
While the availability of athymic mice has made the study of tumor xenografts 
from a range of different hosts possible, the defective cell mediated immunity 
and altered B lymphocyte function of these mice (1) preclude investigations into 
the importance of the immune system in the malignant condition and its 
relationship to invasion and metastasis. Immunocompetent hosts would therefore 
be more suitable for such studies and for others involving manipulation of the 
immune system. In fact, virus producing allografts have been grown in 
immunocompetent chickens (2),guinea fowls (3),turkeys (3) and mice (4,5,6,7) 
but, in all these studies a significant incidence of spontaneous tumour 
remission has been reported. It has however been proposed that spontaneous 
remission of murine allografts 'growing in immunocompetent mice could be 
minimised by the use of suitable highly inbred strains (8). 
The present study therefore aimed to establish such a system with the murine 
sarcoma (MuS) and leukemia (MuL) virus producing line, M52B. This line has 
previously been grown in an outbred Swizz albino (Onderstepoort strain) and 
athymic BALB/c mice (8). Although approximately 10% - 20% of tumours induced in 
the former group regressed spontaneously the number of animals remaining was 
still large enough to make further investigations feasible (8) . Attempts were 
made to reproduce a similar model locally using inbred BALB/c mice obtained from 
the Natal Institute of Immunology (Pinetown). In addition, inbred Boizze, 
randombred BALB/c and outbred mice of the Onderstepoort strain strain were 
included in the study to compare the growth of MS2B cells in mice of these 
genetically differing backgrounds. 
MATERIALS AND METHODS 
Immunocompetent mice of different strains and breeding were used to test the 
tumorigenicity of M52B cells in vivo. Randombred, pregnant BALB/c mice were 
obtained from the animal colony, University of Natal Medical School. Inbred, 
pregnant BALB/c and Biozze mice were purchased from the Natal Institute of 
Immunology, Pinetown, while outbred Swizz mice of the Onderstepoort strain 
strain were obtained from Dr. D. W. Verwoerd, Veterinary Research Institute, 
Onderstepoort. In addition, athymic BALB/c mice obtained from Dr. K. Robinson, 
University of Natal, were used so that tumorigenic properties of M52B cells in 
mice of different immune status could be compared. 
immunocompetent mice were maintained under conventional temperature and humidity 
conditions while athymic mice were housed in an SPF-4 environment. 
Tumours were induced in newborn immunocompetent mice, prior to full development 
of their immune systems, and in weaned (4-6 weeks old) nude mice by the 
•--subcutaneous inoculation of approximately lxlOfo(6) M52B cells in O.lm-e minimum 
essential medium (MEM,FLOW). Mice were injected in the flank region with a 25 
gauge needle. 
Lengths and widths of tumours were measured with Vernier calipers at 2 or 3 day 
intervals. Tumours were palpated regularly to assess spontaneous remission. 
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RESULTS 
Results of this investigation are summarised in Table 1. As anticipated, take 
rates were highest in immunodeficient nude mice. In immunocompetent mice, take 
rates were highest in the inbred strains which were also characterised by the 
shortest latent periods. Spontaneous tumour remission, though not observed in 
nude mice, was a frequent occurrence in all strains of immunocompetent mice, 
being greatest in inbred mice. Although take rates and latent periods were 
similar in inbred BALB/c and Biozze mice, remission rates differed greatly 
between the two, being 66% and 32% respectively. Therefore, in immunocompetent 
mice, used in this study, M52B tumours grew most satisfactorily in the Biozze 
strain i.e. high take rate, short latent period and relatively low percent 
remission. 
DISCUSSION 
Attempts to establish persistant M52B sarcomas in different strains of random-
bred, inbred and outbred immunocompetent mice were not entirely successful as 
approximately 38% of all induced tumours regressed spontaneously within two 
weeks of first appearance. Highest take rates and shortest latent periods were 
observed in inbred strains, but unexpectedly, tumour remission was greatest in 
these mice. Therefore this finding suggests that tumour remission may be 
unrelated to both take rate and latent period, although such an association has 
been previously demonstrated in chickens (2). Furthermore, the use of certain 
inbred strains did not preclude the occurrence of remission although there was 
some association between genetic background and remission rates as fewest 
tumours underwent remission in the inbred Biozze strain. Therefore, of all the 
immunocompetent mice used in this investigation, the Biozze were found to be the 
most suitable hosts for further studies involving the M52B sarcoma. 
In contrast to the findings with immunocompetent mice, all M52B sarcomas induced 
in athymic nude mice grew progressively thus confirming an association between 
inhibition of tumour growth and cell mediated immunity. 
In conclusion, in studies where immunologically compromised mice would be 
unsuitable hosts for M52B tumours, it seems that the inbred Biozze strain from 
the Natal Institute of Immunology would be the most suitable hosts for 
investigations into behaviour and biological properties of these tumours. 
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TABLE 1 : TUMORIGENICITY OF M52B CELLS IN IMMUNOCOMPETENT AND NUDE MICE 











No. of mice inoculated 
No. of mice with tumours 
Take rate (percent) 
Latent period (days) 
Tumour remission: 





















Week 1 x = 1 
Week 2 x = 2 














* Study terminated before three weeks 
9>sioceedLng.4 of the Cle.ctn.on Mi.OA.oyicopy. Society, of. Sou.th.en.ri 
Af/ilca 1985, On fne**. 
"' MORPHOLOGICAL CHARACTERISATION OF A CONTINUOUS MURINE 
SARCOMA LINE 
N.Ramchurren*, S. Bux*'* and K.M. Robinson** 
* Department of Pharmacology, University of Natal, Durban 
** Department of Physiology, University of Natal, Durban 
Cells of the continous M52B murine sarcoma line, which 
produces both murine sarcoma (MuS) and leukaemia (MuL) 
viruses and transplants efficiently in BALB/c mice, were 
obtained from Dr. D. Verwoerd (Onderstepoort). As relatively 
little was known about the M52B cells, this study was 
undertaken to characterise the line with respect to 
tumorigenicity and growth and morphology i_n vivo and in 
vitro. 
All M52B cultures were initiated, using a dry explant 
technique , from subcutaneous solid sarcomas growing in 
immunocompetent BALB/c mice. Cells were maintained in 
Eagle's minimum essential medium (containing 10% foetal calf 
serum and antibiotics) and were inoculated into mice of 
different genetic backgrounds to assess tumorigenicity and 
examine histology. Cultured cells were viewed daily by 
phase-contrast microscopy. Semi-confluent cultures were 
prepared for transmission electron microscopy according to 
the method of Robinson and Gregory . 
Tumours (induced in all mice) were anaplastic sarcomas 
which consisted of pleomorphic compactly arranged spindle 
cells disposed in herringbone patterns. Cultured cells were 
spindle shaped with long cytoplasmic processes. 
Ultrastructural investigation of M52B cells revealed, in 
addition to the prominent nuclei and nucleoli observed by 
phase-contrast microscopy, the presence of short microvilli, 
sparse mitochondria, well developed endoplasmic reticulum-
with annulate lamellae, golgi apparatus, myelin bodies and 
viral particles (Fig. 1). 
Spherical enveloped virus particles with diameters of 
approximately 95nm (Fig. 2) were frequently observed budding 
from the cell surface (Fig. 3). Two different enveloped 
forms were observed, having either electron lucent (20% 
occurrence) or dense (80% occurrence) cores (Fig. 4); 
Non-enveloped, dense structures differing in size and 
morphology were seen in association with microvilli (Fig. 2)'. 
Approximate diameter of these particles was 47nm. Since core 
diameters of the larger putative viruses were similar to 
diameters of the non-enveloped particles, the latter were 
tentatively identified as cores of the larger viruses. All 
non-enveloped particles were dense and therefore thought to 
be related to the larger dense virus particles. 
1 
Although the MuS and MuL viruses have been reported to ! 
be morphologically indistinguishable, the identification ' 
of 2 types of particles in this study makes it tempting to • 
assume that these forms represent the sarcoma and leukaemia ; 
viruses. However, positive identification of each type of 
particle can only be achieved by more direct experimentation,; 
possibly involving biochemical assay^. j 
References: 
1. Robinson, K.M., Haffejee, A. and Angorn, I.B. .(1980) 
Clinc. Oncol. 6_, 125. 
2. Robinson, K.M. and Gregory, M.A. (1977) Proc. Electron 
Microsc. Soc. South Afr. 7, 125. 
3. Gross, L. (1983) Oncogenic viruses, Great Britain, 
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Cultured M52B cells showing nuclei (N) endoplasmic 
reticulum (ER), mitochondria (M) and viral 
particles (V). ; 
Fig. 2 Enveloped (E) and non-enveloped (N) viral particles. 
Fig. 3 Enveloped viral particles (E) budding from cell 
surface. 
Fig. 4a Electron lucent enveloped virus particle. 
Fig. 4b Electron dense enveloped virus particle. 
South. A{Ln.lcan Me.dlc.al Qouinal 1985, 68. On. ?ie.A4 
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1 
SUMMARY 
The effects of gamma-linolenic acid (GLA) on growth of cells 
of the continuous murine sarcoma line M52B were investigated in 
vitro. Prostaglandin (PG) production by these cells following 
GLA treatment was also measured. GLA inhibited the growth of 
M52B cells and became overtly toxic at high doses or after long 
periods of exposure to lower doses. The inhibitory effects of 
GLA were accompanied by an increase in PGE production by M52B 
cells. However, the rise in PGE was not statistically 
significant. Accordingly the extent to which PGE may contribute 
to the inhibition observed with GLA remains unclear. In order to 
establish whether these Ln vitro effects could be reproduced in 
vivo, athymic nude mice bearing murine sarcoma allografts were 
fed either standard laboratory chow or chow supplemented with 35% 
evening primrose oil (EPO) which contains 10% GLA. As there was 
no significant difference in tumour volumes between the two 
groups at the end of the treatment period, the oil enriched diet 




Recent studies have shown that the proliferation of various 
human and murine tumour lines i_n vitro can be inhibited by the 
addition of gam ma-1inolenic acid (GLA) to the culture medium 
(1,2,3,4). Attempts by other workers to reproduce these effects 
in nude mice bearing human tumour xenografts (5) have been 
unsuccessful, though GLA in the form of evening primrose oil 
(EPO) has been reported to suppress growth of allografts in rat 
hosts (6). It has been suggested that the enzyme A-6-desaturase 
which is responsible for the conversion of linoleic acid (LA) to 
GLA might be deficient in malignant cells (Fig. 1). Since GLA is 
a prostaglandin (PG) precursor, inadequate conversion of LA to 
GLA would result in decreased PG production, particularly PGE-̂ . 
Provision of GLA to enzyme deficient malignant cells should 
bypass this blockade, increase PGE-j_ synthesis and reverse cancer 
g r o w t h (7). This study was undertaken, to: 
(1) investigate the i_n vitro effects of exogenous GLA on M52B 
3 
sa r coma c e l l s ; 
(2) d e t e r m i n e w h e t h e r t h e a d d i t i o n of GLA _in v i t r o s i g n i f i c a n t l y 
a f f e c t s PGE p r o d u c t i o n by M52B c e l l s ; 
(3) a s s e s s t h e i_n v i v o e f f e c t s o f d i e t a r y GLA i n t h e f o r m o f 
E P O o n t h e g r o w t h o f M 5 2 B s a r c o m a s i n a t h y m i c 
n u d e ( i m m u n o l o g i c a l l y c o m p r o m i s e d ) (8) a n d i m m u n o c o m p e t e n t 
BALB/c m i c e a n d t h u s d e t e r m i n e a n y i n f l u e n c e o f t h e i m m u n e 
s t a t u s on h o s t r e s p o n s e t o GLA. 
MATERIALS AND METHODS 
M u r i n e s a r c o m a e e l I s . 
T h e m u r i n e s a r c o m a a n d l e u k e m i a v i r u s p r o d u c i n g M52B l i n e 
w a s o r i g i n a l l y o b t a i n e d f r o m D r . D. V e r w o e r d ( O n d e s t e p o o r t ) . 
C e l l s w e r e g r o w n i n 2 5 c m ' 1 G r e m e r t i s s u e c u l t u r e f l a s k s i n 
E a g l e ' s m i m i m u m e s s e n t i a l m e d i u m ( F l o w ) s u p p l e m e n t e d w i t h 10% 
f o e t a l c a l f s e r u m (F low) a n d a n t i b i o t i c s (MEM). C u l t u r e med ium 
was r e p l a c e d a t 3 -4 d a y i n t e r v a l s . 
C e l l s o f t h e M52B l i n e w e r e t u m o r i g e n i c u p o n s u b c u t a n e o u s 
i n o c u l a t i o n of n e w b o r n i m m u n o c o m p e t e n t a n d w e a n e d 4 - 6 w e e k o l d 
4 
nude BALB/c mice. The sarcomatous n a t u r e of the tumours was 
confirmed by l i gh t and t ransmission e lec t ron microscopy. 
Effects of GLA _in v i t r o . 
In v i t r o s tudies were conducted on dense (approximately 2-4 
x 10 c e l l s per f l a sk ) and l e s s dense (approximate ly 1,2 x 10 
c e l l s per f l a sk ) c u l t u r e s of M52B c e l l s . The e f f e c t s of GLA 
(Sigma, L2378) in 0.1M sodium c a r b o n a t e (Na2CC>3)(9) were 
assessed in two ways. 
In the f i r s t exper iment 4 groups of 4 f l a s k s of c e l l s a t 
each densi ty were exposed to a s ingle dose of 5ml MEM containing 
e i t h e r : 
a) no additives 
b) 0.1 ml Na2C03 
c) 50 or 100 ug/ml GLA 
In the second experiment for cells at both densities, 7 
flasks were exposed daily for 3 days to fresh MEM containing 
either: 
a) no additives 
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b) 0.1 ml Na2C03 
c) 10, 20, 30, 40 or 50 ug/ml GLA 
The entire experiment was performed twice. All cultures were 
viewed daily by phase contrast microscopy and observations 
recorded at the end of each experiment. Persisting cells were 
stained with 0.25% May-Grunwald (Gurr) in methanol followed by 5% 
Giemsa (Gurr) in water. 
Radioimmunoassay (RIA) was performed to compare the amounts 
of PGE and PGF released into the medium by GLA treated and 
control cultures. The following procedure was repeated twice. 
Two groups of 3 flasks each were exposed once to 5ml MEM 
containing either 50ug/ml GLA or 0.1ml Na2C03. Twenty-four hours 
later, 2ml samples of MEM from each flask (as well as control MEM 
which had not been in contact with cells) were adjusted with 0.1N 
citric acid to pH 3.5 and extracted 3 times into ethyl acetate. 
After drying under vacuum, samples were subjected to 
chromatography on silicic acid columns according to a 
modification (10) of the method of Mitchell et a]_ (11). RIA of 
PGE and PGF was performed as described by Norman e_t al (12,13). 
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To calculate the amount of PGs released into the medium by cells, 
the control result obtained for MEM not exposed to cells was 
subtracted from all values. Recoveries were monitored with 
tritiated PGFM and were always greater than 75%. 
Cells in all flasks, from which the medium was analysed for 
PGs were lysed osmotically in 0.1% KCl and assayed for protein 
content according to the method of Lowry e_t a_l(14). PG 
production was then expressed as ug/mg protein/24 hours. Since 
anti-PGE2 and anti-PGF2d<antibodies cross-reacted significantly 
with PGE^ and PGF-^ respectively (11), results are reported as PGE 
and PGF and no distinction is drawn between the 1 and 2 series. 
Effects of GLA _in vivo. 
Tumours were induced by inoculating weaned nude and newborn 
immunocompetent BALB/c mice subcutaneously with approximately 10 
M52B cells in 0.1ml medium. Details of tumours established in 
BALB/c mice are represented in Table 1. Since tumour remission 
occurred repeatedly in immunocompetent BALB/c mice, it was only 
possible to determine effects of oral GLA on M52B cells _iri vivo 
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in nude BALB/c mice. EPO which contains 10% GLA (6) was used as 
a source of the fatty acid. Mice in the control group consumed 
standard laboratory chow (National Food Distributors) whereas 
that received by the experimental group was supplemented with 35% 
EPO (3.5% GLA). The approximate rate of food consumption was lOg 
per mouse per day. Diets were supplied ad_ libitum over 10 days. 
Tumour volumes were measured every 48hrs and at the end of the 
experiment after which tumours were excised and examined 
histologically. 
RESULTS 
In vitro Study 
Results of the experiment in which M52B cultures were 
exposed to a single dose of either 50 or lOOug/ml GLA are 
summarised in Table II. Observed changes were related to both 
duration of exposure and concentration of the fatty acid. 
Prior to death, cells often accumulated refractile paranuclear 
granules the lipid nature of which were confirmed by staining 
with Scharlach R. The inhibitory and toxic effects of GLA on 
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growth of M52B cells jLn vitro were more pronounced in less dense 
cultures. 
Results of the experiment in which M52B cultures were 
exposed to multiple doses of GLA are summarised in Table III.. 
Once again, effects were more pronounced in less dense cultures 
and were also dose and time related in all cultures. 
The amounts of PGE and PGF released into the medium by GLA 
treated and control M52B cultures are recorded in Table IV. 
Cells treated with GLA released more PGE and PGF into the medium 
than did controls. However, analysis of results using the Mann 
Whitney U test showed these differences to be statistically non-
significant for both PGE and PGF on two-tailed tests. 
In vivo Study 
Results of the i_n vivo study investigating effects of oral 
GLA on M52B tumours are summarised in Table V and Fig. 2. 
Analysis of data using an unpaired Students t test showed 
differences in tumour volumes between control and treated groups 
to be statistically non-significant both prior to and at the end 
of the experiment. 
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DISCUSSION 
Although growth of M52B cells _in vitro was significantly 
influenced by GLA, growth of solid M52B sarcomas i_n vivo in 
athymic mice was apparently unaffected by the addition of GLA to 
the diet. 
The observed effects of GLA on cell growth iji vitro were 
concentration and time dependent and were more pronounced in less 
dense cultures, presumably as more GLA was available per cell. 
These findings are consistent with results of similar studies 
using human oesophageal carcinoma (1), hepatoma (2) osteogenic 
sarcoma (3) and mouse melanoma (4) cells. However, the mechanism 
by which GLA exerts its action remains obscure. Although the 
present study showed a rise in PGE production by M52B cells 
following GLA treatment this increase was found to be 
statistically non-significant and in addition it was not possible 
to determine whether it was due to PGE-^ or PGE2> Since other 
workers have shown that addition of exogenous PGEs to cells in 
culture inhibits growth (15,16) the increase in PGE recorded in 
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the p r e s e n t s tudy sugges t s t h a t the a c t i o n s of GLA may be 
p a r t i a l l y mediated by PGE. However, the extent to which PGE-j_ may 
be involved remains unclear. 
I t i s p o s s i b l e t h a t the e f f e c t s of GLA on growth observed in 
v i t r o may also be re la ted to a non-specif ic fa t overload as most 
c e l l s demonstrated excessive l ip id accumulation pr ior to death. 
Such an effect would obviously manifest more markedly a t higher 
concentrat ions of the f a t ty acid. 
While GLA has been found to cons i s t en t ly affect the growth 
of mal ignan t c e l l s i_n v i t r o , t h e s e e f f e c t s have g e n e r a l l y not 
been r e p r o d u c i b l e i_n vivo (5,17) , a l though Ghayur e_t a_l_ (6) 
showed t h a t tumour g r o w t h was i n h i b i t e d by s u b c u t a n e o u s 
adminis t ra t ion of EPO to r a t s bearing mammary a l l o g r a f t s . Such 
r e s u l t s were not ob ta ined in the p r e s e n t s tudy us ing a l l o g r a f t 
bearing nude mice. Possible reasons for the conf l i c t ing findings 
may inc lude the fo l l owing . I t i s known t h a t the r a t has a more 
ac t ive A-5-desaturase than the mouse (18) and hence would convert 
exogenous GLA p r e f e r e n t i a l l y to PGE2 (Fig- ! ) • The f i n d i n g s of 
Ghayur e_t a l (6) would then f u r t h e r r e i n f o r c e the argument t h a t 
11 
PGE-|_ alone is not responsible for the inhibitory effect of GLA 
upon the growth of malignant cells. Since nude mice have 
defective cell mediated immunity (8) and prostaglandins are known 
to affect the function of T cells (19), it is not unlikely that 
GLA would produce different effects in animals of different 
immune status. In addition, metabolic differences between the 
allografts, i.e. a sarcoma and a mammary carcinoma (6) may 
influence the effects of the fatty acid. Furthermore, 
administration of dietary rather than parenteral EPO might have 
resulted in inadequate delivery of GLA to the tumour site as fats 
undergo metabolism after oral administration. However, since 
oral EPO was supplemented to. the maximum tolerated extent and 
produced no effect, it would seem that in a clinical situation 
oral doses which would be practical may be ineffective. 
12 
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Fig, Tumour volumes in nude BALB/c mice fed control or EPO 
supplemented diets. 
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Table 1: Tumorigenicity of M52B cells in BALB/c mice 
Number of mice injected 
Latent period (days) 
Take rate (%) 
Remission of tumours by 








Table II Effects of a single dose of GLA on M52B cultures 












png in approximately 
50% cells 




png in approximately 
50% cells 
100% cells dead 
100% cells dead 
100% cells dead 
Control cultures were morphologically unaltered at the end of the experiment. 
nmc = no obvious morphological changes 
png = accumulation of paranuclear granules 
22 
Table III : Effects of multiple doses of GLA on M52B cultures 
Time after addition 
of GLA 
Density of 
cultures lOug/ml 20ug/ml 
Multiple doses of GLA 
30ug/ml 40ug/ml 50ug/n)l 
24 hours 
Dense 
Less dense png in approx-
imately 3 5 % cells 
png in approx-
imately 60% cells 
nmc 
png in approx-
imately 85% cells 
png in approx-
imately 90% cells 
nmc 
png in approx-














imately 70% cells 
100% cells dead 
approximately 80% 
dead cells 
100% cells dead 
100% cells dead 
100% cells dead 
72 hours 
Dense approximately 60% 
cells dead 
Less dense 100% cells dead 
approximately 80% 
cells dead 
100% cells dead 
100% cells dead 
100% cells dead 
100% cells dead 
100% cells dead 
100% cells dead 
100% cells dead 
Control cultures were morphologically unaltered at the end of the experiment. 
nmc = no obvious morphological changes 
png = accumulation of paranuclear granules 
Table IV: Amounts of prostaglandins (PGs) released into the 
medium by control and GLA treated M52B cultures 
PGs (ug/mg protein/24hr) 
PGE 
M52B Cultures 











Table V: M52B tumour volumes in nude BALB/c mice receiving EPO 
and control diets before and after the treatment 
period 
Tumour Volume 
Mean ± SEM (mm 
Before treatment After treatment 
Control 
(n = 14) 662 +. 737 8464 ± 171! 
EPO 
(n = 15) 911 +. 357 10025 + 2194 
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